---
document_datetime: 2023-09-21 17:56:31
document_pages: 77
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/masican-epar-public-assessment-report_en.pdf
document_name: masican-epar-public-assessment-report_en.pdf
version: success
processing_time: 39.1133767
conversion_datetime: 2025-12-28 00:29:02.099397
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

8 May 2014 EMA/174182/2014 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Masican

International non-proprietary name: MASITINIB

## Procedure No. EMEA/H/C/002670/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:                 | Masican                                                                                                                                                                        |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | AB Science 3, Avenue George V 75008 Paris FRANCE                                                                                                                               |
| Active substance:                              | Masitinib mesylate                                                                                                                                                             |
| International Nonproprietary Name/Common Name: | MASITINIB                                                                                                                                                                      |
| Pharmaco-therapeutic group (ATC Code):         | Antineoplastic agents, protein kinase inhibitors (L01XE22)                                                                                                                     |
| Therapeutic indication:                        | Masican is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after progression with imatinib treatment. |
| Pharmaceutical form):                          | Film-coated tablet                                                                                                                                                             |
| Strengths:                                     | 100 mg and 200 mg                                                                                                                                                              |
| Route of administration:                       | Oral use                                                                                                                                                                       |
| Packaging:                                     | bottle (HDPE)                                                                                                                                                                  |
| Package size:                                  | 30 tablets                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                       | 6                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6          |                                                                                                          |
| 1.2. Manufacturers......................................................................................................8      |                                                                                                          |
| 1.3. Steps taken for the assessment of the product.........................................................8                   |                                                                                                          |
| 1.4. Steps taken for the re-examination procedure                                                                              | .........................................................9                                               |
| 2. Scientific discussion..............................................................................                         | 10                                                                                                       |
| 2.1. Introduction.......................................................................................................10     |                                                                                                          |
| 2.2. Quality aspects                                                                                                           | ..................................................................................................10     |
| 2.2.1. Introduction....................................................................................................10      |                                                                                                          |
| 2.2.2. Active substance                                                                                                        | .............................................................................................10          |
| Manufacture.............................................................................................................11     |                                                                                                          |
| Specification.............................................................................................................12   |                                                                                                          |
| Stability...................................................................................................................12 |                                                                                                          |
| 2.2.3. Finished medicinal product................................................................................13            |                                                                                                          |
| Pharmaceutical development......................................................................................13             |                                                                                                          |
| Adventitious agents...................................................................................................14       |                                                                                                          |
| Manufacture of the product                                                                                                     | ........................................................................................14               |
| Product specification                                                                                                          | .................................................................................................14      |
| Stability of the product                                                                                                       | ..............................................................................................14         |
| 2.2.4. Discussion on chemical, and pharmaceutical aspects............................................15                        |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                      | ......................15                                                                                 |
| 2.2.6. Recommendation for future quality development.................................................16                        |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                      | ............................................................................................16           |
| 2.3.1. Introduction....................................................................................................16      |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                            | .................................................................................................16      |
| 2.3.3. Pharmacokinetics.............................................................................................19         |                                                                                                          |
| 2.3.4. Toxicology                                                                                                              | ......................................................................................................22 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                               | .........................................................27                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................27              |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................30                |                                                                                                          |
| 2.4. Clinical aspects                                                                                                          | ..................................................................................................30     |
| 2.4.1. Introduction....................................................................................................30      |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................32         |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................35            |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................36                |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................36                 |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                         | ..................................................................................................37     |
| 2.5.1. Dose response studies......................................................................................37           |                                                                                                          |
| 2.5.2. Main studies                                                                                                            | ...................................................................................................38    |

<div style=\"page-break-after: always\"></div>

| 2.5.3. Discussion on clinical efficacy............................................................................51        |    |
|-----------------------------------------------------------------------------------------------------------------------------|----|
| 2.5.4. Conclusions on the clinical efficacy.....................................................................52          |    |
| 2.6. Clinical safety ....................................................................................................52 |    |
| 2.6.1. Discussion on clinical safety ..............................................................................59       |    |
| 2.6.2. Conclusions on the clinical safety.......................................................................62          |    |
| 2.7. Pharmacovigilance..............................................................................................62      |    |
| 2.8. Risk Management Plan........................................................................................62         |    |
| 2.9. User consultation ...............................................................................................65    |    |
| 3. Benefit-Risk Balance.............................................................................                        | 66 |
| 4. Recommendations.................................................................................                         | 69 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse events

AUC

Area under Curve

CI

Confidence Interval

Cl

Clearance

Cmax

Maximum concentration

CR

Complete Response

CV

Coefficient of Variation

CYP

Cytochrome p450

DDR1

Discoidin domain receptor 1

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

F

Bioavailability

GIST

Gastrointestinal Stromal Tumour

HPLC

High Performance Liquid Chromatograph

HR

Hazard ratio

MTD

Maximum tolerated dose

OS

Overall Survival

PD

Progressive disease

PDGFR

Platelet-derived growth factor receptor

PFS

Progression Free Survival

P-gp

Permeability glycoprotein

PR

Partial Response

SAE

Serious adverse events

SD

Stable Disease  / Standard Deviation

TKI

Tyrosine Kinase Inhibitor

tmax

Time to maximum concentration

Vd

Volume of distribution

WT

Wild Type

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant AB Science submitted on 2 July 2012 an application for Marketing Authorisation to the  European  Medicines  Agency  (EMA)  for  Masican,  through  the  centralised  procedure  falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 17 November 2011.

Masican was designated as an orphan medicinal product EU/3/04/251 on 21 December 2004. Masican was designated as an orphan medicinal product in the following indication: treatment of malignant gastro intestinal stromal tumours.

The applicant applied for the following indication: Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after progression with imatinib treatment.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that masitinib was considered to be a new active substance.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and bibliographic literature substituting/supporting certain tests or studies.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/014/2012 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's requests for consideration

## Conditional Marketing Authorisation

The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14(7) of the above mentioned Regulation based on the

<div style=\"page-break-after: always\"></div>

following claim(s):

The Applicant has provided a document justifying that the medicinal product falls within the scope of the conditional marketing authorisation Regulation (Article 2) and that the requirements for conditional marketing authorisation are fulfilled (Article 4), in particular:

- The applicant considered that the benefit-risk balance for masitinib in treatment of GIST was considered favourable: The pivotal AB07001 study demonstrated superiority of masitinib over sunitinib in terms of overall survival (OS).
- At the time of the registration request, three studies have been evaluated: the pivotal AB07001 phase II study, the supportive AB03002 phase I study, and the supportive AB04016 phase II study.
- The unmet medical needs will be fulfilled and the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required: Despite the survival benefits brought about by imatinib and second-line treatments for imatinib-resistant patients, GIST remains a serious and life-threatening disease with a real unmet medical need for patients.
- The applicant proposed to complete and confirm clinical results already obtained in the pivotal study with a confirmatory phase III study. This confirmatory phase III study is a prospective, multicentre, randomized, open-label, active-controlled, two-parallel groups, study in patients with gastrointestinal stromal tumour after progression with imatinib up to 800 mg/day bid.

## New active Substance status

The applicant requested the active substance masitinib (as mesylate) contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union.

## Protocol Assistance

The applicant received Protocol Assistance from the CHMP on 12 January 2005, 30 August 2005 and 19 July 2011. The Protocol Assistance pertained to quality, non-clinical and clinical aspects of the dossier.

## Licensing status

The product was not licensed in any country at the time of submission of the application.

<div style=\"page-break-after: always\"></div>

## 1.2. Manufacturers

## Manufacturers responsible for batch release

Centre Spécialités Pharmaceutiques (CSP) 76 avenue du midi FR-63802 Cournon d'Auvergne Cedex France Excella GmbH Nuernberger Str. 12 90537 Feucht GERMANY

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur:   Jens Ersbøll Co-Rapporteur:   Greg Markey

- The application was received by the EMA on 2 July 2012.
- The procedure started on 18 July 2012.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 12 October 2012. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 16 October 2012.
- During the meeting on 15 November 2012, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 November 2012.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 23 May 2013.
- The final GCP Integrated Inspection Report (IIR) of the inspection carried out at two investigator sites (inspection dates 10-14 December 2012 and 7-11 January 2013) and the sponsor site in France (inspection dates 14-18 January 2013) was issued on 22 March 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 11 July 2013.
- During the PRAC meeting on 11 July 2013, the PRAC adopted an RMP Advice and assessment overview.
- During the CHMP meeting on 25 July 2013, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 23 September 2013.

<div style=\"page-break-after: always\"></div>

- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding issues to all CHMP members on 3 October 2013.
- During  the  PRAC  meeting  on  10  October  2013,  the  PRAC  adopted  an  RMP  Advice  and assessment overview.
- During the CHMP meeting on 21 October 2013, outstanding issues were addressed by the applicant during an oral explanation before the CHMP.
- During the meeting on 21 November 2013, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a Marketing Authorisation to Masican.

## 1.4. Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: David Lyons

Co-Rapporteur: Pierre Demolis

- The applicant submitted written notice to the EMA on 29 November 2013 to request a reexamination of Masican CHMP opinion of 21 November 2013.
- During its meeting on 19 December 2013 the CHMP appointed David Lyons as Rapporteur and Pierre Demolis as Co-Rapporteur.
- The applicant submitted the detailed grounds for the re-examination on 20 January 2014 . The re-examination procedure started on 21 January 2014.
- The Rapporteur's Assessment Report was circulated to all CHMP members on 12 February 2014. The Co Rapporteur's Assessment Report was circulated to all CHMP members on 13 February 2014.
- During a meeting of the Scientific Advisory Group (SAG) Oncology on 5 March 2014, experts were convened to consider the grounds for re-examination.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's detailed grounds for re-examination to all CHMP members on 28 February 2014.
- The Applicant submitted additional argumentation in response to the quality assessment outcome included on the Joint Assessment Report on 18 March 2014.
- During the CHMP meeting on 18 March 2014, the detailed grounds for re-examination were addressed by the applicant during an oral explanation before the CHMP.
- During the meeting on 20 March 2014, the CHMP, in the light of the scientific data available and the scientific discussion within the Committee, the CHMP re-examined its initial opinion and in its final opinion concluded that the application did not satisfy the criteria for authorisation and did not recommend the granting of the marketing authorisation .
- The revised final Opinion was adopted by the CHMP with written procedure on 8 May 2014.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Gastrointestinal stromal tumours (GIST) are uncommon sarcomas. KIT, and to a lesser extent Platelet-derived  growth  factor  receptor (PDGFR),  are  the  oncogenic  driving  force  in  the tumourigenesis of GIST. Activating KIT mutations occur in at least 80 to 85% of GIST and the majority  (70%)  of  these  KIT  mutations  are  located  in  the  juxtamembrane  domain  (exon  11). About 10% of KIT mutations in GIST are found in exon 9 and they lead to the same functional consequences as exon 11 mutations. PDGFR mutations are reported in about 3% of patients.

Treatment  of  GIST  includes  complete  surgical  resection,  which  is  curative  in  a  proportion  of patients.  However,  recurrence  is  common  and  conventional  chemotherapy  is  not  particularly effective. The introduction of molecular targeted therapies tyrosine kinase inhibitors (TKIs) has revolutionised  the  treatment  of  patients  with  unresectable  and/or  metastatic  malignant  GIST (imatinib) and patients with unresectable and/or metastatic malignant GIST after the failure of imatinib treatment due to resistance or intolerance (sunitinib). There is currently no standard of care in the setting of resistance to both these medicinal products.

Masitinib (AB1010) is a protein tyrosine kinase inhibitor (TKI). In vitro, masitinib inhibits the cKit wild type (WT) and its mutated forms (exon 9 and 11), as well as the platelet-derived growth factor alpha (PDGFRA) receptor.

In  this  application,  AB  Science  requested  the  approval  of  masitinib  for the  treatment  of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after progression with imatinib treatment .

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product was proposed as film-coated tablets containing 100 mg and 200 mg of masitinib (as mesylate) as active substance.

Other ingredients are: microcrystalline cellulose (Avicel pH101 and pH200), povidone, crospovidone magnesium stearate and the film-coating containing notably, titanium dioxide, talc, polyethylene glycol and sunset yellow lake (E110)).

The product is available in high density polyethylene (HDPE) bottles with child resistance closures at a pack size of 30 tablets.

## 2.2.2. Active substance

The active substance masitinib mesylate was stated to have been synthesised at four different manufacturers using the same synthetic route. Ultrafine manufactured batches of masitinib mesylate for toxicological trials only and Archemis batches were used in phase 1 and some phase

<div style=\"page-break-after: always\"></div>

2 clinical studies. Manufacturing was then transferred from Archemis to Biocon Limited, India as Archemis ceased the production of masitinib mesylate. Two current manufacturers were initially proposed for the commercial scale manufacture of masitinib mesylate: Biocon Limited, India and Excella GmbH, Germany. The Biocon batches were used for some phase 2 and then phase 3 studies while Excella batches were used for phase 3 studies.

Full information of masitinib mesylate manufacture and control was submitted in section 3.2.S.3 to support the quality of Biocon as a manufacture of the active substance. The applicant removed this source from the marketing authorisation application after the Day 120 List of Questions adopted by CHMP.

An ASMF for masitinib mesylate was submitted by Excella GmbH for masitinib mesylate. A letter of access to the ASMF in relation to the application for the proposed 100 mg and 200 mg filmcoated tablets was provided. The discussion below refers to this source alone, as it is the only proposed for marketing.

The chemical name of masitinib mesylate is 4-[(4-methyl-piperazin-1-yl)methyl]-N-(4-methyl-3{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}-phenyl)benzamide, methane sulphonic acid salt and has the following structure:

<!-- image -->

The molecular structure of masitinib mesylate has been confirmed by elemental analysis, IR, HNMR and LC-MS using a reference batch of masitinib mesylate.

Masitinib mesylate is a white to pale yellow powder, slightly hygroscopic, practically insoluble in acetone, slightly soluble in ethanol, sparingly soluble in methanol and soluble in water.

The molecular structure does not contain asymmetric carbon atoms.

Three polymorphic forms of masitinib mesylate were identified by Differential Scanning Calorimetry and X-ray spectrometry. The masitinib mesylate is consistently manufactured as polymorphic Form DRX1, anhydrous and the most stable. The polymorphic forms can be differentiated by melting point/range. Melting point is included in the active substance specification.

## Manufacture

The synthesis is comprised of 6 steps (with step 4 being divided into 3 sub-steps). Steps 1 to 4.1 are synthetic steps (bond breaking/formation), steps 4.2 to 6 comprise purification and salt formation.

<div style=\"page-break-after: always\"></div>

Most of starting materials are acceptable. One of the starting material is considered a complex molecule and should instead be considered as intermediate of the synthesis. The description of its synthesis was provided and it was identified that its manufacture has potential to significantly impact the impurity profile of the active substance. Hence, redefining of this starting material was needed. The applicant failed to address the major objection on the redefinition of the starting material.

Other minor concerns on the manufacture of active substance, control of intermediates and declared batch size were left outstanding.

Due to the above, the information on the manufacturing of the active substance could not be considered satisfactory.

## Specification

The active substance specification includes tests for: appearance, identity (IR, HPLC), assay (HPLC/UPLC), impurities (HPLC/UPLC), residual solvents (GC), water content (KF), heavy metals (Ph. Eur.), particle size (laser diffraction), melting point (DSC) and residue on ignition (Ph. Eur.).

The remaining analytical methods were adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines.

Unsatisfactory data was submitted to support the individual limit of not more than 0.10 % for two impurities. Similarly the limit proposed for unspecified impurities  cannot be accepted as it is not in accordance to the applicable guidance considering the maximum daily dose of 1200 mg of masitinib. These two major concerns are still outstanding.

A major concern was left outstanding on the adequacy of the proposed particle size distribution specification.

Batch analysis data (pilot scale, n=4) of the active substance were provided. The results were consistent from batch to batch.

## Stability

Stability data on three pilot scale batches of active substance from the proposed manufacturer stored sealed transparent PE bags inside a PE/aluminium bag, with a desiccant in between the bags, for up to 24 months under long term conditions at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided.

The following parameters were tested: appearance, identification, melting point, water content, assay and related substances. The analytical methods used were the same as for release and were stability indicating.

A photostability study in accordance with EU/ICH Q1B was conducted showing that the active substance is not photo labile. Forced-degradation studies demonstrated that solutions of the active substance were sensitive towards heat, UV-light, heat &amp; acid and heat &amp; hydrogen.

<div style=\"page-break-after: always\"></div>

The stability results indicate that the active substance manufactured by the proposed supplier(s) is sufficiently stable and that there is no shift of its polymorphic form. The stability results justify the proposed retest period in the proposed container.

## 2.2.3. Finished medicinal product

The 100 mg and 200 mg finished product are both presented as light orange, capsule shaped, double debossed film-coated tablets. The 100 mg is debossed with 'C)' on one side and '100' on the other side. The 200 mg finished product is debossed with 'C)' on one side and '200' on the other side.

## Pharmaceutical development

During Phase I studies 100 mg of masitinib mesylate was delivered in a manually filled size 1 capsule with no other excipients. In order to reduce the size of the formulation and to accommodate a higher strength, tablet formulations were developed. The manufacture of the medicinal product was transferred from Catalent (USA) to Excella (DE) during the clinical trials.

The formulation development was deficient and different concerns were raised, see below.

The excipients proposed are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards (with the exception of Opadry coating agent). The compatibility studies of the active substance were not sufficient to support the compatibility of this new active substance with the excipients in the formulation. This issue remained as unresolved.

There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

The particle size of the active substance and core tablet hardness of the batches used in the clinical trials and batches of both strengths manufactured as proposed for the market vary significantly. The data provided comparing the dissolution profiles between batches was not able to bridge data between the different versions of the product, nor support the specification proposed for these parameters. This is of serious concern as the bioavailability of the active substance was not proven to be consistent between batches and no extrapolation to the intended critical quality attributes for commercial manufacture was possible.

The applicant failed to submit data in support of the discriminatory nature of the dissolution method. This is of major concern as the comparability exercise between biobatches and batches manufactured according to the details included in Module 3 are not validated, moreover commercial batch release testing would not be able to detect batches with a potential jeopardized product performance.

The primary packaging is HDPE bottles closed with a polypropylene child resistance closure with an induction sealed aluminium/polyethylene liner, where the polyethylene side is in contact with the tablets. The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

<div style=\"page-break-after: always\"></div>

## Adventitious agents

No excipients derived from animal or human origin have been used.

## Manufacture of the product

The manufacturing process consists of 8 main steps: weighing, preparation of binder solution, granulation, drying, milling, compression, tablet coating and packaging. The process is considered to be a standard manufacturing process.

Critical steps in the manufacturing process have been identified. The appropriateness of the inprocess controls for the proposed manufacturing process cannot be verified due to the several issues detailed in this report.

No process validation data was provided, this is justified as the manufacturing process of masitinib follows a standard wet granulation process, moreover one evaluation batch of each strength has been manufactured and shown to be compliant with the finished product specification. A satisfactory process validation protocol was provided, as required by current guidance.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form, such as appearance, identification, (HPLC, UV), average weight, uniformity of dosage units (Ph. Eur.),  dissolution,  moisture  content,  hardness,  assay  and  impurities  (HPLC),  microbiological quality (Ph. Eur.).

The validation data provided for analytical method was not sufficient with regards the methods for related substances determination and dissolution.

The finished product specification covers appropriate parameters for this dosage form and is broadly acceptable. However, some issues remain unresolved.

Major objections remain with regards the limit still to be defined for impurity, found to be threshold-dependent genotoxic. Other concerns are outstanding for the specifications of tablet hardness and total impurities.

Batch analysis results are provided for two batches of 100 mg and five batches of 200 mg tablets manufactured at the proposed commercial manufacturing site, at commercial scale, confirming the consistency of the manufacturing process.

Minor concerns on the description and control of the container closure system remain unresolved.

## Stability of the product

Stability data of one batch of finished product of 100 mg and three batches of 200 mg batches of finished product (all at commercial scale) stored under long term conditions up to 24 months at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided. The batches of medicinal product are

<div style=\"page-break-after: always\"></div>

representative to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for appearance, moisture content, assay of masitinib, impurity content and dissolution.

Force degradation was carried out in various stress condition as part of the analytical validation. The data showed that degradation was observed in acidic, alkaline and oxidative conditions. Satisfactory mass balance data showed that the analytical procedure for impurities is stability indicating.

In addition, photostability studies showed a slight fading of the colour of film-coating; however the proposed HDPE primary packaging offers sufficient protection from light exposure.

Based on available stability data, the shelf-life of 36 months when stored in the original container to protect from moisture and light are acceptable.

## 2.2.4. Discussion on chemical, and pharmaceutical aspects

A number of major and minor objections on the data submitted in support of the quality of the active substance and finished product remain unresolved despite being raised at the several stages of the procedure and the different attempts from the active substance manufacture and applicant to resolve them. These issues relate to, inter alia , the unsatisfactory regulatory control of the manufacture and specification of the active substance, in itself and as intended to be used in the medicinal product; deficient data supporting the bridging of biobatches with the product intended for commercial release, control of consistence manufacture to the intended product performance, control of impurities and validation of analytical methods.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is not considered to be acceptable. Physicochemical and biological aspects relevant to the uniform clinical performance of the product were not demonstrated.

At the time of the opinion the CHMP has identified a number of non-resolved quality related issues, which precluded positive conclusions on the quality data provided.

The applicant failed to address the major objection on the redefinition of the starting material used in the synthesis of the active substance. Inadequate control of starting materials has potential to significantly impact the impurity profile of the active substance.

The bioavailability of the active substance was not proven to be consistent between batches and no extrapolation to the intended critical quality attributes for commercial manufacture was possible. Furthermore, the applicant failed to provide data in support of the discriminatory nature of the dissolution method. This is of major concern as the commercial batch release testing would not be able to detect batches with a potential jeopardized product performance.

In addition the applicant failed to justify limits proposed for the impurities, including potential genotoxic impurities. This deficiency was also considered critical.

<div style=\"page-break-after: always\"></div>

In view of the above listed limitations and other minor quality related unresolved issues, the CHMP concluded that the quality of the product was not sufficiently demonstrated.

## 2.2.6. Recommendation for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The goal of the nonclinical studies was to support the registration of masitinib for the treatment of GIST.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

Pharmacodynamic studies were conducted aimed at demonstrating masitinib's inhibitory potential against its primary targets, c-Kit and PDGFR. Both in vitro and in vivo experiments were performed. A comparison was presented between masitinib and the two other TKIs currently marketed in the treatment of non-resectable GIST, namely imatinib and sunitinib.

In vitro AB1010 was a potent and selective inhibitor of both WT and mutated c-Kit. It was an inhibitor of the catalytic activity of the c-Kit kinase, being able to block the phosphorylation of a peptide substrate as well as the phosphorylation of the receptor kinase itself. This inhibitory activity resulted in an anti-proliferative activity in cell lines expressing the c-Kit receptor. AB1010 also selectively inhibited the autophosphorylation of JM mutant c-Kit and c-Kit WT while requiring higher concentration (&gt;10 µM) for the inhibition of catalytic domain mutant forms of Kit.

Masitinib was a selective kinase inhibitory compound. Twelve kinases are targeted by masitinib: Type III receptors tyrosine kinases (Kit and its closely related homologs CSF1R, PDGFRα and PDGFRβ; DDRs receptors, which are known to be targeted by the majority of kinase inhibitory compounds and SFKs: LYN, FYN, LCK, FRK, FGR and BLK. An in vitro study showed that AB1010 inhibition is highly selective for c-Kit in comparison to other kinases (including: EGFR, RET, TRKB, FGFR1, FGFR3, and FLT3).

The N-desmethyl derivative of AB1010, which is the main plasma metabolite found in animals and humans after oral administration of AB1010, retains the activity and selectivity profiles of the parent compound. This compound may contribute to the in vivo therapeutic activity of AB1010.

The evaluation of the anti-proliferative and pro-apoptosis effects of AB1010 on various mammalian cell lines expressing mutated and WT c-Kit revealed that AB1010 inhibited SCF induced proliferation of c-Kit WT cells and the spontaneous proliferation of cells expressing c-Kit

<div style=\"page-break-after: always\"></div>

mutated in the JM domain, but did not affect the growth of c-Kit mutated in the catalytic domain nor control cells such as T lymphocytes and Ku812. The absence of an effect on human T lymphocyte proliferation suggests that AB1010, when used at low concentrations, does not have a pronounced non-specific cytotoxic activity resulting from the inhibition of key cellular kinases, common to many cells and essential for general mechanisms such as mitogenesis. These data indicate that AB1010 inhibits the proliferation of cells that express JM mutations on c-Kit, with an IC50 in the nM range. AB1010 was also shown to be a potent inhibitor of Kit WT and JM mutated Kit, which induces apoptosis. The potent inhibitory action of AB1010 on c-Kit kinase activity, as showed in  an in vitro enzymatic assay and a HMC1 α 155 cell proliferation assay, is thought to be responsible for the inhibition of both cell proliferation and colony formation. AB1010 showed a complete inhibition of tyrosine phosphorylation of c-Kit in Target Mast cells. The investigation of anti-proliferative and pro-apoptosis activities of AB1010 on cell lines rendered resistant to imatinib revealed that these experiments suggest that imatinib-resistant cell lines (Ba/F3 mKit Δ27 imatinib-resistant cells) remain sensitive to higher concentration of AB1010 but not to imatinib, while the parental cell lines are highly sensitive to both imatinib and AB1010. AB1010 also induced apoptosis of imatinib-resistant Ba/F3 Δ27. A comparison of in vitro efficacy of masitinib as compared with sunitinib and imatinib on c-Kit WT and c-Kit mutants associated with GIST revealed that AB1010 efficiently inhibits spontaneous proliferation of cells expressing activated mutant c-Kit found in GIST. These include c-Kit mutated in the JM domain (human c-Kit V559D) and in the extracellular domain (human c-Kit AY502-503) (IC50=5 nM and 40 nM, respectively). AB1010 is slightly more potent towards c-Kit WT and mutants GIST including the T670I resistance mutants (secondary resistance) when compared to imatinib. AB1010 is less efficient than sunitinib on c-Kit WT and mutants. However, masitinib is more selective and does not inhibit kinases that are linked to toxic events such as Abl kinases. Two in vivo studies were conducted in order to evaluate the antitumor activity of masitinib in nude mice (female Balb/cNu/Nu mice) that were subcutaneously grafted with a transgenic murine hematopoietic cell line (i.e. Ba/F3 transfected with the gene encoding Kit JM Δ27) following per os and IP administration. In the first study AB1010 given twice a day for ten consecutive days resulted in a marked inhibition of tumour growth at all doses levels. In addition, AB1010 at either the mid- or top-dose resulted in a complete resorption of the tumour at completion of the 10-day treatment. In the second study the antitumor activity of masitinib was tested following two types of administration: intraperitoneal injection (IP) and per os in a nude mice model. AB1010 at 30 mg/kg IP induced a potent inhibition of tumour growth with a significant increase in survival. AB1010 induced a marked tumour growth inhibition in a dose dependent manner. A marked tumour growth inhibition occurred at 30 and 45 mg/kg.  AB1010, given per os twice a day at 100 mg/kg for five consecutive days, completely blocked tumour growth. AB1010 demonstrated a strong anti-tumour activity on Ba/F3 Δ27 tumours.  AB1010 showed an anti-tumour activity regardless of the tumour volume at the beginning of the treatment and for both IP and oral route.

## Secondary pharmacodynamic studies

Studies and references were submitted with respect to masitinib properties on inhibition of the

<div style=\"page-break-after: always\"></div>

Discoidin domain receptor 1 (DDR1) receptors which appears to be involved in the homing of tumoural cells in hepatic metastasis; inhibition of mast cells since they appear to be involved in the tumour microenvironment where they release e.g. pro-angiogenic mediators; inhibition of c-Kit signalling in immature dendritic cells, which may promote dendritic cell-mediated NK cell activation; inhibition of the Lyn/FAK pathway which is implicated with cell proliferation and migration. In addition, a reference was submitted which described how imatinib and sunitinib induce secretion of anti-inflammatory cytokine IL-10 in macrophage cultures, indicating that treatment with these inhibitors might contribute to an immune suppressive microenvironment in GIST.

## Safety pharmacology programme

The results from the safety pharmacology studies conducted with masitinib are presented in the table below.

Table 1 - Safety pharmacology studies

| Organ System Evaluated (Study Report No.) GLP-status   | Species/ Number                               | Dose/ Method of Administration              | Results                                                                                                                                                                                                                                                                                                                            | NOAEL               |
|--------------------------------------------------------|-----------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Cardiovascular system (2-24367-sac) GLP                | Beagle dogs/6 females/group                   | 10, 50, 150 mg/kg p.o. (gavage) single dose | 3/6 and 6/6 animals vomited within an hour after administration of 50 and 150 mg/kg, respectively. Hence, any treatment-related effect on CV parameters could not be evaluated at 150 mg/kg. No effect on heart rate, diastolic, systolic and mean arterial blood pressure or duration of PQ, QRS, QT intervals when evaluated via | 50 mg/kg p.o. (n=3) |
| hERG channel (4-ps05d91) GLP                           | 4 cells/group                                 | 0.1, 1, 10, 30 µmol/L                       | implantation of telemetric devices. Masitinib inhibited the hERG tail current by 8%, 14%, 54% and 73% at 0.1, 1, 10 and 30 µM in HEK cells stably expressing the hERG potassium channel. IC 50 : 8.3 µM Positive control: E-4031 (0.1                                                                                              | <0.1 µM             |
| Respiratory System (1-24366-sar) GLP                   | Conscious Sprague-Dawley rats/8 females/group | 15, 50, 150 mg/kg p.o. (gavage) single dose | No effect on respiratory rate, peak inspiratory and expiratory flows, tidal volume, minute volume or enhanced pause when measured using whole body plethysmography.                                                                                                                                                                | 150 mg/kg p.o.      |
| Central nervous system (3-24368-sar) GLP               | Sprague-Dawley rats/ 8 females/group          | 15, 50, 150 mg/kg p.o. (gavage) single dose | No effect observed in a functional observation battery. Positive control: chlorpromazine (10 mg/kg)                                                                                                                                                                                                                                | 150 mg/kg p.o.      |

## Pharmacodynamic drug interactions

No non-clinical studies evaluating the potential for pharmacodynamic drug interactions have

<div style=\"page-break-after: always\"></div>

been submitted.

## 2.3.3. Pharmacokinetics

## Absorption

In  vitro studies  in  Caco-2  cells,  indicated  that  masitinib  may  be  a  substrate  of  P-gp  mediated transport at concentrations &lt;10 μM. At higher concentrations (≥10 μM), masitinib appeared to be  an  inhibitor  of  P-gp  mediated  transport  which  was  likely  to  be  due  to  saturation  of  P-gpmediated  efflux.  It  was  not  possible  to  establish  an  exact  IC50,  however  approximated  IC50 values were calculated, and in the range of 63.24 to 154.22 µM. The free fraction of masitinib in plasma was well below this  range,  hence  inhibition  of  systemic  P-gp  was  considered  unlikely, whereas the concentration of masitinib in the gut was much higher than the approximated IC50 values, and inhibition of P-gp in the gut was a risk.

The absorption of masitinib was studied after single i.v. and p.o administration of 14 C-masitinib to Beagle dogs and Sprague-Dawley rats. No gender differences were observed following single p.o. and i.v. dosing to rats and dogs. Mean Tmax following p.o. dosing was 2.2 h in dogs and 4 h in rats.  Elimination  half-life  (T½)  following  oral  administration  was  4.6  h  and  10.4  h  in  rats  and dogs, respectively. The bioavailability was relatively high with a mean value of 83% in dogs and 72% in rats following a single p.o. administration.  Masitinib displayed a relatively large volume of distribution (Vd) with values of 10.2 and 6.38 L/kg for male and female Sprague-Dawley rats, respectively.  The  plasma  clearance  for  male  and  female  rats  was  19.8  and  14.8  mL/min/kg, respectively.

Gender  differences  were  observed  in  rats  following  repeated  dosing  hence  higher  masitinib plasma exposure levels were observed in females relative to males and Tmax occurred earlier. Plasma exposure to the major metabolite AB3280 on the other hand was around 2-fold higher in males than in females. Moreover, AB3280 Tmax varied from 3-4 h while the elimination half-life varied  from  3.55  to  4.23  h.  No  gender  differences  were  observed  with  respect  to  masitinib absorption in dogs following repeated oral administration.

## Distribution

The  binding  to  human,  rat,  mouse,  dog  and  rabbit  plasma  proteins  was  high  with  93.93%, 92.15%,  86.12%,  93.33%  and  97.5%,  respectively  and  not  saturable  within  the  applied masitinib concentration range (0.2-5 µM). In plasma, binding to human serum albumin was high (48.91%) while a lower binding occurred on α1-acid-glycoprotein (8.4%) and gamma-globulin (1.8%).  In  human  blood,  the  free  fraction  was  constant  at  2.12%  as  long  as  the  protein concentration did not vary. Preliminary data indicate that 88% of AB3280 is bound to human plasma proteins.

Following  oral  administration  of  10  mg/kg 14 C-masitinib  to  Sprague-Dawley  rats,  quantifiable levels of radioactivity (which decreased with time) were found in all tissues at 24 hours except for muscle and/or brain. Radioactivity levels were above quantifiable limits in most tissues at 168 hours.  The  highest  levels  were  seen  in  the  adrenals,  kidneys,  spleen  and  intestines  of  both sexesand pancreas of males while lower levels were found in the pancreas of females and skin, lymph nodes, stomach, thymus and ovaries of the males and/or females.

<div style=\"page-break-after: always\"></div>

A single dose study in rats showed that radio labelled masitinib crossed the blood-brain barrier to a  very  limited  extent  where  it  was  rapidly  eliminated  (not  detectable  48  hours  following administration).

## Metabolism

## In vitro metabolites

The Phase I metabolism of masitinib was investigated in hepatic microsomes from CD-1 mice, Sprague-Dawley rats, New Zealand White rabbits, Beagle dogs, Cynomolgus monkeys and humans. While the identical five metabolites were detected in mice and rabbits (AB3280, MET1, MET2, MET3 and AB1187.3), four metabolites were seen in rats, monkeys and humans (AB3280, MET1, MET2, MET3). While AB3280 was the major metabolite in hepatic microsomes derived from mice, rats, monkeys and humans ( ≥ 18%), AB3280 was not formed in dog hepatocytes in vitro. Hence, the dog microsomes formed MET1, MET2 and MET3. No human specific metabolites were detected.

In addition, the Phase I and II metabolism of masitinib was studied in hepatocytes from CD-1

mice, Sprague-Dawley rats and humans. While AB3280 was the major metabolite in hepatocytes from rats and humans AB2436 was the major metabolite in mice hepatocytes in vitro (&gt;47%). AB2436 was less abundant in rats (16%) and it was not formed in human hepatocytes. Moreover, MET1/AB5235, which is genotoxic in the presence of S9 fraction in vitro, was only detected in mouse hepatocytes. Again, no human specific metabolites were observed.

## In vivo metabolites

In in vivo i.v. and p.o. metabolite studies conducted in rats and dogs, no masitinib plasma metabolites were detected. The applicant ascribes the lack of detectable masitinib metabolites, the poor sensibility of the analytical method. Still, the major metabolite AB3280 was quantified during the course of repeat-dose studies in mice, rats and dogs. Based on the sum of in vitro data, plasma, urinary and faecal data, an overview of the expected metabolism of masitinib in mice, rats, dogs and humans has been gathered. N-demethylation of masitinib to AB3280 takes place in mice, rats, dogs as well as humans and AB3280 represents the major masitinib metabolite in plasma. Based on the presence of  AB2436 and/or its counterpart AB1187.3 in urine, the cleavage of the amide bond leading to the formation of AB1187.3 and the aniline AB2436 occurs in all species tested. N-oxidation and hydroxylation appear to be minor metabolic pathways. N-oxides of either masitinib or AB3280 or both, were found as minor metabolites in urine and faeces of rats and dogs and were not specifically searched for in plasma of any species. Hydroxylated derivatives of masitinib were identified as minor metabolites in urine and faeces of rats and dogs.

## Excretion

The excretion of 14 C-masitinib was evaluated in rats and dogs over a 168 hour period. No gender differences in excretion pattern were observed (data not shown). Following i.v. dosing of rats, the radioactivity in the faeces and urine was eliminated fast with &gt;81% of the total recovered dose in the faeces and urine being excreted within 24 hours following injection. Similarly, the administered radioactivity was excreted relatively rapidly following p.o. dosing with &gt;91% of the total recovered dose in faeces being eliminated within the first 48 hours after

<div style=\"page-break-after: always\"></div>

oral gavage while &gt;84% of the total recovered dose in urine was excreted within 24 hours.

## Pharmacokinetic drug interactions

## Identification of the major drug metabolising enzymes involved in the human hepatic metabolism of masitinib (SR-1-abs-02, GLP)

In order to identify which cytochrome P450 (CYP) enzymes(s) are responsible for the metabolism of masitinib, 14C-masitinib (5 μM) was incubated with liver microsomes prepared from 16 individual donors, CYP-selective chemical inhibitors and recombinant CYP450 enzymes (CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4). In addition, it had been verified that the liver microsomes expressed CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5 and 4A11 activity. Radiolabelled masitinib was metabolized to up to 4 discrete metabolite fractions of which the major metabolite was identified as AB3280 (N-desmethyl masitinib) based upon cochromatography with non-radiolabelled AB3280 reference standard. Further analysis showed that CYP3A4/5 was the enzyme primarily responsible for the metabolism of masitinib. The data also indicated that CYP2C8 has the capacity to catalyse the formation of AB3280 from masitinib.

## Evaluation of CYP450 inhibitory properties of masitinib and AB3280 (SR-2-pr6513-3vt2081, GLP)

The CYP450 inhibitory properties of masitinib and AB3280 towards CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5 were investigated in human liver microsomes. CYP3A4/5 inhibition was studied using three different substrates i.e. midazolam, testosterone and nifedipine. Neither CYP1A2, 2C8, 2C19 nor 2E1 were inhibited at masitinib concentrations up to 5 µM while CYP2C9 was inhibited with IC50 values in ≥17.5 µM. Masitinib was a weak to moderate inhibitor of CYP3A4/5 and CYP2C9, as well as CYP2D6 with IC50 values of 14 μM, 20 μM and &gt; 30 μM, respectively. This inhibition was partly reversible. Moreover, AB2380 showed no inhibitory potential towards CYP450 isotypes at concentrations up to 2 μM.

## Evaluation of CYP450 induction properties of masitinib and AB3280 (SR-3-pr6537-5vt2085, GLP)

The activities of CYP1A2, 2C9, 2C19 and 3A4/5 enzymes in human hepatocytes were evaluated before and following a 3 to 4-day incubation period with masitinib or AB3280. In one of two tested hepatocyte batches, masitinib treatment (500 and 1000 ng/mL) gave rise to a 20-60% decrease of CYP3A4/5 activity. Similarly, treatment with AB3280 (1000 ng/mL) resulted in a 20% decrease in CYP3A4/5 activity. Moreover, AB3280 treatment resulted in a 10-20% decrease in CYP2C9 activity at 500 and 1000 ng/mL.

## P-gp

Masitinib was incubated with cultured Caco-2 cell monolayers grown on membrane supports (transwells) in a 24 well format to investigate its potential as a P-gp substrate and inhibitor. Masitinib was assessed as a potential substrate for P-gp transport at 1, 50 and 500 μM by determining the apparent permeability (Papp) for Apical - Basolateral (A-B) transport and for Basolateral - Apical (B-A) transport in the presence and absence of verapamil (a known P-gp transport inhibitor).

Masitinib was assessed as a potential inhibitor of P-gp transport at 1, 10 and 100 μM by determining the apparent permeability (Papp) for Apical - Basolateral (A-B) transport At lower

<div style=\"page-break-after: always\"></div>

concentrations (&lt;10 μM), Masitinib appears to be a substrate of P-gp mediated transport. At higher concentrations (≥10 μM), AB1010 appears to be an inhibitor of P-gp mediated transport, likely to be due to saturation of P-gp-mediated efflux.

## Other transporters

There are no data on the possible influence on other transporters.

## 2.3.4. Toxicology

## Single dose toxicity

Single-dose toxicity studies conducted in rats showed that the approximately lethal dose in rats is 2000 mg/kg following p.o. administration and higher than 100 mg/kg following i.v. dosing.

## Repeat dose toxicity

Repeat dose toxicity studies have been conducted of 4, 13 and 26 weeks duration in the rat and 4, 13 and 39 weeks duration in the dog. Repeated dose toxicity studies were performed in the mouse up to 3 months duration.

In these studies the principal target organ toxicity findings attributed to treatment with masitinib concerned  the  bone  marrow,  the  liver  and  the  kidney  in  dogs  and  rats,  gastrointestinal  tract intolerance in dogs, the female genital tract in rats and the male genital tract in dogs. At higher dose-levels these findings were accompanied by bodyweight changes and mortality.

Bone marrow toxicity observed in mice, rats and dogs was characterized by a reduction in red blood  cell  parameters  (reductions  in  red  blood  cells,  haemoglobin  and  packed  cell  volume),  a reduction in white blood cells (leucocytes, lymphocytes  and  neutrophils),  bone  marrow hypocellularity  in  rats  and  dogs  as  well  as  clinical  signs  in  the  form  of  pallor  and  abnormal breathing in the dog. Haematological effects were observed at doses ≥ 10 mg/kg/day in rats and dogs.

Liver  weight  increase  and  hepatocellular  hypertrophy  was  noted  in  mice,  rats  and  dogs.  This finding was accompanied by a moderate ( ≥ 2-fold) increase in liver enzymes (ALT/AST) at doses ≥ 100 and ≥ 150 mg/kg/day in rats and dogs, respectively. Moreover, reversible bile canalicular plugs were noted in dogs treated with 50 mg/kg masitinib for 4 weeks.

Renal  toxicity  was  observed  in  rats  and  dogs.  In  rats,  protein  in  the  urine,  increased  urine volume  and  pH,  increased  kidney  weight,  increases  in  plasma  creatinine  and  urea  as  well  as degenerative/necrotic nephropathy were observed with an overall NOAEL of 10 mg/kg/day. In dogs, presence of protein and blood in the urine and a reduction in urinary pH were observed with a NOAEL of 10 mg/kg/day. In the mouse there was urinary bladder urothelial hyperplasia in male mice which was not fully reversible during a recovery period.

Masitinib exerted gastrointestinal toxicity in the dog in the form of vomiting, regurgitation and soft/liquid  faeces.  In  addition,  reddish  or  greenish  coloured  faeces  were  observed  in  dogs administered 150 mg/kg/day for 4 weeks. As for the majority of anti-cancer treatment, nausea, diarrhoea and vomiting are very common findings in patients treated with masitinib.

<div style=\"page-break-after: always\"></div>

Female genital organs showed morphological changes indicative of oestrous cycle disturbance in rats from 10 mg/kg/day. At 100 mg/kg/day, the ovaries had moderate to large number of luteal and/or follicular haemocysts, no or few corpora lutea, and very few or few follicular development. Depending on ovarian stage, this was associated with endometrial cell atrophy or hypertrophy together with vaginal epithelial cell hyperplasia, hyperkeratinisation or mucification. Ovary weight was increased and on the macroscopic level, discoloured and enlarged ovaries were observed.

Following 39-weeks treatment with 30 mg/kg/day masitinib, vacuolation of the epithelium in the seminiferous  tubules  and  oligospermia  in  the  epididymides  were  observed  in  dogs.  Most  male Beagle dogs are sexually mature by eight to nine months of age and since the animals applied in the 39-week dog study were 6 to 7 months at study initiation the majority were sexually mature at sacrifice (1 male out of 4 was pubertal).

Slight to moderate hyperostosis were observed in the bones of rats administered 100 mg/kg/day for 6 months.

The repeated dose toxicity studies revealed myocardial degeneration and fibrosis in the rat 26 week study and pericardial oedema in 1/4 female dogs at the top dose in the 39 week study. In the 2 year rat carcinogenicity study cardiomyopathy/atrial fibrosis occurred in both sexes at the mid-and top-dose levels and was considered to be a contributing factor to death in 5/50 males and 2/50 females at the top dose level. The severity of the cardiomyopathy appeared to be dose dependent, however, the frequency was not increased compared to the control group. Masitinib treatment in this study increased the severity of the underlying cardiomyopathy.

## Genotoxicity

The results from the genotoxicity studies are given in the table below.

Table 2 - Genotoxicity studies

| Type of test/study ID/GLP                             | Test system                                                            | Concentration range/ Metabolising system                                                                                                                                                                                                                       | Results   |
|-------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Gene mutations in bacteria/SR-1- 24351/GLP            | Salmonella strains TA1535, TA1537, TA98, TA100, TA102 E. Coli WP2 uvrA | Experiments without S9 WP2 uvrA: 156.3-2500 μg/plate TA98, TA100: 19.53-312.5 μg/plate TA1535, TA1537, TA102: 39.06-625 μg/plate Experiments with S9 WP2 uvrA: 312.5-5000 μg/plate TA1537, TA100: 19.53-312.5 μg/plate TA98, TA102, TA1535: 39.06-625 μg/plate | Negative  |
| Gene mutations in mammalian cells/SR-2- 24352/GLP     | Human lymphocytes                                                      | Experiments without S9 3 h treatment/20 h harvest: 2.29-20.58 µg/mL 20 h treatment/20 h harvest: 2.5-10 µg/mL 44 h treatment/44 h harvest: 30 µg/mL Experiments with S9 3 h treatment/20 h harvest: 2.29-30 µg/mL 3 h treatment/44 h harvest: 30 µg/mL         | Negative  |
| Gene mutations in mammalian cells/SR-3-24354- mly/GLP | L5178Y TK +/- mouse lymphoma cells                                     | Experiments without S9 3 hours treatment: 1.3-20 µg/mL 24 h treatment: 0.16-7.5 µg/mL                                                                                                                                                                          | Negative  |

<div style=\"page-break-after: always\"></div>

|                                                     |                                                | Experiments with S9 3 h treatment: 2.5-40 µg/mL                                       |          |
|-----------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------|----------|
| Chromosomal aberrations in vivo/SR-1-24353- mas/GLP | Mouse, micronuclei in bone marrow; 5/sex/group | 437.5, 875, 1750 mg/kg/day for two days p.o. (gavage) Sacrificed 24 h after treatment | Negative |

## Carcinogenicity

Long-term carcinogenicity studies conducted with mastinib in CD-1 mice and Sprague-Dawley rats.

Masitinib-treatment was associated with mortality in the mice. Hence, the overall survival rates ranged from 26-38% in the treated animals versus 40% in the control group. Due to high mortality rates, the study treatment period and the administered doses were reduced. Urinary bladder transitional carcinomas and papillomas were seen in 5/52 male CD-1 administered 500/300/80 mg/kg/day masitinib for 80 weeks, while transitional papillomas were observed in the intermediate dose group (150/100/40 mg/kg/day). Urinary bladder transitional cell hyperplasia was also seen in 150/100/40 and 500/300/80 mg/kg/day males and females with a greater incidence than in controls and 30/20 mg/kg/day mice. As the tumours were seen only in treated animals, with a clear dose-relationship, in association with pre-neoplastic finding in males and females, in incidences far outside from historical control data and with statistically positive trend, they were attributed to treatment with masitinib. A NOAEL for the urinary bladder transitional carcinomas was established at 30/20 mg/kg/day.

While masitinib treatment was not associated with significant mortality in the long-term rat carcinogenicity study, it induced uterine adenocarcinomas and atypical uterine hyperplasia with a NOAEL of 30 mg/kg/day. Thyroid follicular cell adenomas were observed in 1/50 and 5/50 female rats administered 30 and 75/60 mg/kg/day, respectively. These finding was accompanied by follicular cell hyperplasia hence the overall NOAEL is considered 10 mg/kg/day. Pulmonary cystic keratinizing epithelioma was found in 4/50 high-dose females whereas it was not recorded in the CIT control data or in the compilation of spontaneous neoplasms of control Sprague-Dawley rats from Charles River Laboratories (2004) and therefore was considered to be induced by masitinib.

## Reproduction Toxicity

An overview of  the  performed  reproductive  and  developmental  toxicity  studies  is  given  in  the table below.

Table 3 - Reproductive and developmental toxicity studies

| Study type/ Study ID / GLP                                   | Species; Number Female/ group        | Route & dose               | Dosing period                              |    | Major findings                                                                      |   NOAEL (mg/kg/day ) |
|--------------------------------------------------------------|--------------------------------------|----------------------------|--------------------------------------------|----|-------------------------------------------------------------------------------------|----------------------|
| Male fertility/SR- 1-26311-rsr/GLP but not the bioanalysis   | Sprague-Dawley rat; 24 males/group   | 10, 30, 100 mg/kg/day p.o. | 29 days prior to mating female sacrifice   | -  | None                                                                                |                  100 |
| Female fertility/SR-1- 26311-rsr/GLP but not the bioanalysis | Sprague-Dawley rat; 24 females/group | 10, 30, 100 mg/kg/day p.o. | 29 days prior to mating day 7 post- coitum | -  | ↓ fertility indices, ↓ corpora lutea, ↓ implantation sites, ↑ pre-implantation loss |                   10 |

<div style=\"page-break-after: always\"></div>

| Female fertility/SR-2- aa19859/GLP                                   | Sprague-Dawley rat; 25 females/group       | 15, 50 mg/kg/day p.o.   | 28 days followed by a recovery period of two weeks before mating   | Acyclic oestrous cycle                                                                                    | 15              |
|----------------------------------------------------------------------|--------------------------------------------|-------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------|
| Embryo-fœtal development/SR- 1-29395-rsr/GLP but not the bioanalysis | Sprague-Dawley rat; 24 females/group       | 10, 30, 100 mg/kg/day   | Day 6 - 17 post- coitum                                            | F0: ↓ body weight gain, ↓ food consumption, macroscopic findings F1: ↓ foetal weight, skeletal variations | F0: <10 F1: 30  |
| Embryo-fœtal development/SR- 2-29398-rsl/GLP but not the bioanalysis | New Zealand White rabbit; 22 females/group | 10, 30, 100 mg/kg/day   | Day 6 - 18 post- coitum                                            | F0: ↓ body weight F1: skeletal variations                                                                 | F0: <10 F1: 100 |

GD, gestation day

No treatment-related effect on mating parameters, the reproductive organs or seminology was noted at doses up to 100 mg/kg/day in male Sprague-Dawley rats treated p.o. from 29 days prior to mating. Female Sprague-Dawley rats were treated p.o. with 10, 30 or 100 mg/kg/day masitinib from 29 days prior to mating until day 7 post-coitum. There were no effects on mating behaviour, whereas the fertility of females given 100 mg/kg/day was affected, as indicated by the number of non-pregnant females (3/24, compared to 0/24 in the vehicle), the low number of corpora lutea and implantation sites and the high pre-implantation loss. At 100 mg/kg/day, the increased  number  of  early  resorptions  in  addition  to  the  increased  number  of  dead  concepti resulted in a low number of live concepti. The microscopic examination of the ovaries showed haemocysts in many corpora lutea in all the females given 100 mg/kg/day. Cystic degeneration of corpora lutea (with accumulation of fibroblasts and a few erythrocytes) was seen at 100 and 30  mg/kg/day (respectively,  17/24  and  6/24  females).  The  adverse  effects  on  female  fertility appeared reversible hence acyclic oestrous cycle was the only finding in female Sprague-Dawley rats were given p.o. 15 and 50 mg/kg/day masitinib for 28 days followed by a recovery period of two weeks before mating.

Overall, the NOAEL for male and female fertility is considered 100 mg/kg/day and 10 mg/kg/day, respectively.

The  potential  effects  of  masitinib  on  embryo-foetal  development  were  evaluated  in  rats  and rabbits. In the rat study, a lower (-10%) mean foetal body weight was observed in the high-dose group (100 mg/kg/day). While visceral or skeletal malformations were not observed, masitinibtreatment was associated with variations in the form of unossified or incompletely ossified bones of  the  head,  sternebrae  and  ribs.  The  incomplete  ossifications  were  observed  at  doses  ≥  30 mg/kg/day. Maternal toxicity was observed in the form of a significant reduction in body weight gain  at  100  mg/kg/day.  Moreover,  maternal  macroscopic  findings  were  made  in  all  masitinibtreated  groups.  Cases  of unossified  foetal  bone  (5th  and  6th  sternebra)  were  observed  in the rabbit  embryo-foetal  development  study  at  doses  ≥  30  mg/kg/day.  Maternal  toxicity  was observed at 100 mg/kg/day in the form of a 74% reduction in overall body weight gain relative to  control  animals.  Moreover,  all  pregnant  females  experienced  a  mean  net  body  weight  loss

<div style=\"page-break-after: always\"></div>

(body weight change adjusted for gravid uterus weight) from day 6 post-coitum, but this was markedly greater than control at 100 mg/kg/day.

Since the skeletal variation observed (cases of unossified bone) are reversible and as such not adverse to the animal, the NOAEL for developmental toxicity is considered 30 mg/kg/day based on the reduced foetal weight observed in rats. The NOAEL for maternal toxicity (reduced body weight/macroscopic findings) is considered &lt; 10 mg/kg/day.

## Toxicokinetic data

While  control  samples  collected  in  the  4-week  and  13-week  repeat-dose  toxicity  studies conducted in rats were not analysed for the presence of masitinib, very low levels of masitinib (namely 1.51, 4.34, and 8.37 ng/mL) were detected in three control animals included in the 26 weeks repeat-dose toxicity study in rats. These levels were much lower than those quantified in the test-treated groups and were attributed to test item contamination.

A low level of masitinib (1.64 ng/mL) was detected in a single plasma sample (2 h) collected on study day 28 from a control animal included in the 4-week study in dogs. However, no masitinib was  detected  in  plasma  samples  from  control  animals  included  in  the  13-week  and  39-week studies conducted with masitinib in dogs.

An overview of the toxicokinetic data obtained in the repeat-dose toxicity studies conducted with masitinib was provided (data not shown).

## Local Tolerance

## Evaluation of skin sensitization potential in mice using the local lymph node assay (LLNA):

Masitinib induced delayed contact hypersensitivity in the murine Local Lymph Node Assay. According to the EC3 value obtained in the experiment (0.7%), masitinib should be considered as a strong sensitizer when applied on the skin.

Acute dermal irritation in rabbits: Masitinib was slightly irritant when applied topically to rabbits for up to 72 hours. Hence, mean scores over 24, 48 and 72 hours were 0.3, 1.0 and 0.7 for erythema and 0.0, 0.0 and 0.0 for oedema.

Acute eye irritation in rabbits: Masitinib was severely irritant when administered by ocular route to rabbits.

## Other toxicity studies

The masitinib metabolite AB3280 was devoid of a genotoxic potential in tests for gene mutations in  bacteria  (Ames  test)  and  in  mammalian  cells  (cultured  human  lymphocytes).  Moreover, AB3280 at  doses  up  to  600  mg/kg  only  gave  rise  to  minor  findings  in  a  2-week  repeat-dose toxicity  study  in  rats.  However,  the  aniline  metabolite  AB2436  gave  rise  to  gene  mutations  in both bacteria and human lymphocytes in the presence of S9.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Ecotoxicity/environmental risk assessment

Table 4 - Summary of main study results

| Substance (INN/Invented name): masitinib/Masican       | Substance (INN/Invented name): masitinib/Masican   | Substance (INN/Invented name): masitinib/Masican   | Substance (INN/Invented name): masitinib/Masican   |
|--------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| CAS-number (if available): 790 299-79-5                | CAS-number (if available): 790 299-79-5            | CAS-number (if available): 790 299-79-5            | CAS-number (if available): 790 299-79-5            |
| PBT screening                                          |                                                    | Result                                             | Conclusion                                         |
| Bioaccumulation potential- log K ow                    | potentiometric (pH-metric) technique               | 3.75                                               | Potential PBT (N)                                  |
| Phase I                                                |                                                    |                                                    |                                                    |
| Calculation                                            | Value                                              | Unit                                               | Conclusion                                         |
| PEC surfacewater refined (e.g. prevalence, literature) | 0.002 to 0.004                                     | µ g/L                                              | < 0.01 threshold (N)                               |

The PEC surfacewater value for masitinib is below the action limit of 0.01 µg/L and is not a PBT substance as log Kow does not exceed 4.5.

## 2.3.6. Discussion on non-clinical aspects

Mutations in the KIT gene have been identified in approximately 80-85% of GIST, indicating a critical role in the pathogenesis of GIST. Some GISTs with wild-type KIT genotype present mutations in the platelet-derived growth factor-alpha (PDGFR-α) kinase. These mutations lead to gain of function and ligand independent constitutive activity of the receptor and consequently to tumour growth and cell proliferation. Using recombinant truncated c-Kit, it was shown that masitinib was a competitive inhibitor of c-Kit tyrosine kinase activity with an IC50 of 200 nM.

Studies in transfected Ba/F3 cells as well as cell lines expressing wild-type and mutant c-Kit showed that masitinib is a potent (IC50&lt; 0.15 µM) inhibitor of proliferation of cells expressing wild-type c-Kit as well as c-Kit mutated in exon 9 (fifth extracellular domain) and exon 11 (juxtamembrane region). Moreover, the proliferation of Ba/F3 cells expressing PDGFRα and an EGF-PDGFRβ construct was inhibited with IC50 values of 0.25 nM and 10 nM, respectively. Masitinib was less active in cells expressing c-Kit mutated in the exon 17 (catalytic domain). Overall, masitinib appears to be a slightly more potent inhibitor of cells expressing wild-type as well as mutated c-Kit when compared to imatinib. It should be noted however that the majority of the results were based only on duplicate determinations.

In a study comparing the anti-proliferative effects of masitinib, imatinib and sunitinib, sunitinib was the most potent inhibitor of proliferation of Ba/F3 cells expressing human wild-type c-Kit, mutated c-Kit (exon 9 or 11) or wild-type human PDGFRα. Similarly, masitinib displayed slightly more potent anti-proliferative effects than imatinib. Neither of the tested kinase inhibitors was able to inhibit c-Kit mutated in the catalytic domain (T670I mutation).

Masitinib was a potent (IC50≤ 0.2 µM) inducer of apoptosis in cells expressing wild-type c-Kit and c-Kit with mutations in the juxtamembrane domain whereas cells expressing c-Kit mutated in the catalytic domain were not affected.

<div style=\"page-break-after: always\"></div>

The anti-tumour activity of masitinib was evaluated in female nude mice bearing BA/F3 c-Kit Δ27 subcutaneous (s.c.) tumours. Following twice daily p.o. treatment of small size tumours, the tumour doubling time was 1 day and 2 days in the vehicle and 10 mg/kg treatment groups, respectively, while tumour stabilization was observed at doses ≥ 30 mg/kg twice daily. Similarly, the anti-tumour activity of masitinib was evaluated in mice with large tumours. Twice daily p.o. treatment with 100 mg/kg for 5 days resulted in a tumour doubling time of 5 days in the vehicle control group while tumour stabilization was obtained in the 100 mg/kg masitinib group. Similarly, tumour growth inhibition (T/C%) of 19%, 0.4%, 0.4% was observed in BA/F3 c-Kit Δ27 bearing nude mice treated with 50, 100 and 200 mg/kg masitinib twice daily for 10 days. In the secondary pharmacology section alternative modes of action through which masitinib may impact tumour maintenance and evasiveness were discussed. However, it remains to be demonstrated that these potential secondary mechanisms of action play a role in the antitumour activity of masitinib. Safety pharmacology studies in rats revealed no treatment-related effect on the central nervous system or respiratory system at single oral doses up to 150 mg/kg. Masitinib induced a concentration-dependent reduction in hERG tail current over the concentration range 0.1 to 30 µM. Considering a masitinib free fraction in human blood of 2.12%, the reported clinical plasma Cmax of 1206 ng/mL masitinib corresponds to an unbound plasma concentration of approximately 51.3 nM. Hence, only a minimal effect on the hERG channel is expected at clinical Cmax. No effect was observed on electrocardiogram parameters in telemetered dogs (n=3) receiving 50 mg/kg. This dose level roughly corresponds to the recommended daily dose for patients receiving masitinib. No non-clinical studies on the potential for pharmacodynamic drug interactions were conducted. However this was considered acceptable, since masitinib will not be co-administered with drugs which have an identical pharmacological target and/or have similar or opposing pharmacodynamic effects. An overview of the expected metabolism of masitinib in mice, rats, dogs and humans has been gathered.  N-demethylation  of  masitinib  to  AB3280  takes  place  in  mice,  rats,  dogs  as  well  as humans and AB3280 represents the major masitinib metabolite in plasma. Overall, the major metabolites detected in humans were also formed in animals and as such the species used for toxicity testing are considered valid animal models. The Applicant has not provided a quantitative comparison of the metabolite levels detected in humans and the species used for toxicity testing. Since  no  human  specific  metabolites  have  been  detected,  this  was  acceptable  as  no  further metabolite  qualification  studies  was  required  since  masitinib  is  intended  for  the  treatment  of advanced cancer (ICH S9 guidance). should be included in drug interaction considerations.

The plasma protein binding was high in all species: more than 90% in human plasma and more than  85%  in  dog,  mouse  and  rat  plasma.  The  free  fraction  of  AB3280  in  animal  plasma  was about  twice  as  high  as  in  human  plasma.  The  applicant  should  provide  an  estimate  of  the expected  contribution  of  AB3280  to  the  in  vivo  efficacy  and  an  assessment  as  to  whether  it While the genotoxic metabolite AB2436 as well as its genotoxic metabolite AB5235 was detectable in the urine of mice, only AB2436 was detected  in  rat  urine  and  neither  metabolite  could  be  found  in  rat  plasma.  Similarly,  these

<div style=\"page-break-after: always\"></div>

metabolites  were  not  detected  in  human  plasma,  while  AB2436  was  found  in  human  urine (AB5235 was not analysed for in human urine). The provided in vitro and in vivo data show that the genotoxic aniline metabolites AB2436 and AB5235 are formed predominantly in mice but to a lower  extent  in  rats  and  humans.  According  to  the  Applicant,  0.05%  of  the  administered masitinib dose (molar units) was detected as AB2436 in human urine.

Masitinib  was  predominantly  excreted  via  the  faeces  (around  90%  of  the  administered  dose) following p.o. and i.v. administration to rats and dogs.

In vitro studies showed that CYP3A4/5 was the enzyme primarily responsible for the metabolism of masitinib. The data also indicated that CYP2C8 has the capacity to catalyze the formation of AB3280 from masitinib.

The  CYP450  inhibitory  properties  of  masitinib  and  AB3280  towards  CYP1A2,  2C8,  2C9,  2C19, 2D6, 2E1 and 3A4/5 were investigated in human liver microsomes. Neither CYP1A2, 2C8, 2C19 nor 2E1 were inhibited at masitinib concentrations up to 5 µM while CYP2C9 was inhibited with IC50 values in ≥17.5 µM. Masitinib was a weak to moderate inhibitor of CYP3A4/5 and CYP2C9, as well as CYP2D6 with IC50 values of 14 μM, 20 μM and &gt; 30 μM, respectively. This inhibition was partly reversible. It is not possible to conclude if inhibition is competitive or non competitive. The risk of inhibition of hepatic enzymes is very low, due to the limited free fraction in plasma, whereas  the  inhibition  in  the  gut  is  a  risk  due  to  high  concentrations  of  masitinib  prior  to absorption  from  the  gut.    AB2380  showed  no  inhibitory  potential  towards  CYP450  isotypes  at concentrations up to 2 μM.

Based  on  an in  vitro study  in  human  hepatocytes,  masitinib  neither  increase  the  activity  nor induce  the  levels  of  expression  of  CYP1A2,  CYP2B6  or  CYP3A4  at  concentration  up  to  10  µM (cytotoxicity occurred at 30 µM).

Repeat dose toxicity studies have been conducted of 4, 13 and 26 weeks duration in the rat and 4, 13 and 39 weeks duration in the dog. Repeated dose toxicity studies were performed in the mouse  up  to  3  months  duration.  In  these  studies  the  principal  target  organ  toxicity  findings attributed to treatment with masitinib concerned the bone marrow, the liver and the kidney in dogs and rats, gastrointestinal tract intolerance in dogs. These findings were also reported in the clinical setting. Findings also concerned the female genital tract in rats and the male genital tract in  dogs.  At  higher  dose-levels,  these  nonclinical  findings  were  accompanied  by  bodyweight changes and mortality.

The repeated dose toxicity studies revealed myocardial degeneration and fibrosis in the rat 26 week study and pericardial oedema in 1/4 female dogs at the top dose in the 39 week study. In the 2 year rat carcinogenicity study cardiomyopathy/atrial fibrosis occurred in both sexes at the mid-and top-dose levels and was considered to be a contributing factor to death in 5/50 males and 2/50 females at the top dose level. The severity of the cardiomyopathy appeared to be dose dependent, however, the frequency was not increased compared to the control group. Masitinib treatment in this study increased the severity of the underlying cardiomyopathy.

Since  the  bioanalysis  conducted  in  the  26-week  study  in  rats  and  the  39-week  study  in  dogs were  not  performed  under  GLP  conditions,  the  toxicokinetic  data  from  these  studies  are  only considered  indicative.  Still,  the  overall  toxicokinetic  data  indicate  that  while  the  bone  marrow toxicity,  renal  toxicity,  reproductive  toxicity  in  male  dogs  and  oestrous  cycle  disturbances  in

<div style=\"page-break-after: always\"></div>

female rats occurred at or below clinically relevant exposure levels, small to moderate (3 to 10fold) exposure margins may exist for the observed liver toxicity, ovarian toxicity, hyperostosis and myocardial toxicity.

Masitinib was non-genotoxic in a test battery comprising the following assays: Ames test, human lymphocytes, L5178Y TK+/- mouse lymphoma cells and in vivo mouse micronuclei test.

Although not required for an anti-cancer drug intended for treatment of advanced cancer, the Applicant submitted long-term carcinogenicity studies conducted with masitinib in CD-1 mice and Sprague-Dawley rats. Overall, based on the presently available data, it could not be excluded that masitinib may exert a carcinogenic effect in humans.

Masitinib did not affect the fertility of male rats. In female rats, in the general toxicity studies, masitinib was shown to disrupt ovarian function as evidenced by haemorrhagic ovarian follicular cysts seen in several studies. This disruption may be the cause of reduced fertility observed in the Segment I study. The 'return to fertility' study suggested that the ovarian dysfunction was rapidly  reversible.  In  the  Segment  I  study,  there  was  evidence  of  increased  post-implantation loss in treated rats, indicating an embryotoxic action. This was not observed in the Segment II studies  in  rats  or  rabbits.  In  the  rat  segment  II  study,  treatment  with  AB1010  resulted  in reduced  litter  weight  and  reduced  ossification.  These  findings  may  be  indicative  of  slightly delayed  development,  as  a  consequence  of  maternal  toxicity.  There  was  no  evidence  of teratogenicity in the rat or the rabbit, over dose-levels up to those causing maternal toxicity.

Three studies were conducted to assess local tolerance. In an acute dermal irritation study masitinib mesylate was found to be a slight irritant when applied topically to rabbits. Masitinib mesylate was severely irritating when administered by the ocular route to rabbits. Masitinib mesylate showed skin sensitization potential in a murine LLNA.

Based on the environmental risk assessment, masitinib is not expected to pose a risk to the environment.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the nonclinical data submitted was adequate. However, further information would be required with regards to plasma protein binding and metabolites.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The applicant claimed that the clinical trials were performed in accordance with GCP. Following review of the documentation, the CHMP requested a triggered GCP inspection. It was found that all  subjects  signed  informed  consents  before  enrolment.  The  main  findings  of  the  inspection carried out in December 2012 are briefly summarised below:

<div style=\"page-break-after: always\"></div>

- The result of the first clinical trial site inspection was a total of 23 findings. There were 6 critical, 11 major and 6 minor findings. As the main focus during the inspection was the pivotal trial AB07001 all the findings relate to this trial.
- The result of the second clinical trial site inspection was a total of 15 findings. There were 4  critical,  9  major  and  2  minor  findings.  All  findings  have  relation  to  the  pivotal  trial AB07001 and 3 of the critical findings did also relate to the supportive trial AB04016.
- The result of the sponsor site inspection was a total of 43 findings. There were 13 critical, 25 major and 5 minor findings. One critical finding relates to trial AB04016 only, all other findings are related to trial AB07001 or both of them.
- The overall result of the three inspections was a total number of 81 findings; 23 critical, 45 major and 13 minor findings. All findings, except one, had relevance for the pivotal trial AB07001.

In terms of the recommendation for the acceptability of the clinical trial data, the following was stated:

The inspection revealed critical deficiencies, which raise concerns about the efficacy and safety data  reported  in  the  CSR  of  the  pivotal  trial  AB07001  for  investigator  sites  01  and  03  (22 patients' records out of 43 patients in total in the trial representing 51% of the patients in this pivotal trial).

Inspectors cannot recommend that the presented data and CSR is accepted by the CHMP or used for further assessment.

The sponsor and investigators have declared in their responses that they are in the process of re-monitoring  trial  AB07001  in  the  aim  'to  release  error-free  data  listings  from  which  an updated version of the CSR will be written and communicated to the competent authorities'.

Most  of  the  unreported  or  misreported  data  are  present  at  sites  and  can  be  collected  or corrected. Visit windows can however not be changed and assessors has to evaluate if this can have any impact on the PFS.

The  Applicant,  in  response  to  the  inspector's  findings,  provided  a  follow-up  of  the  post inspection corrective action plan. The Applicant has responded to the numerous GCP inspection findings with corrective measures whenever possible.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

| Type of study      | Study number      | Location in eCTD    | Objective(s) of the study                                                                                                   | Study Design and Type of Control   | Testproduct, dosage regimen,route of administration                      | Nunber of subjects         | Healthy subjects or diagnosis of patients                                  | Duration of treatiment        | Study status, type of report   |
|--------------------|-------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------|-------------------------------|--------------------------------|
| BA                 | AB1010- PIHV04015 | 5.3.1.1             | to compare therelative BA of AB1010 from two formulations (capsule or tablet)                                               | Cross over                         | Tablet, Capsules, 100mg,oral                                             | 12                         | healthy volunteers                                                         | Single dose                   | Complete, Full                 |
| BE                 | AB1010- PIHV05031 | 5.3.1.2             | to evaluate the food intake influence on pharmacokinetic profiles                                                           | Cross over                         | Tablet, 200mg, oral                                                      | 12                         | healthy volunteers                                                         | Single dose                   | Complete, Full                 |
| PK                 | AB1010- PIHV03001 | 5.3.3.1             | todeterminesafety/ tolerabilityand 1PK parameters of AB1003                                                                 | Double blind, placebo- controlled  | powder for solution, ascending doses (40,100, 200, 400 and 800 mg), oral | 40                         | healthy volunteers                                                         | Dose escalations, single dose | Complete, Full                 |
| PK                 | AB1010- PIHV03003 | 5.3.3.1             | todeterminesafety/ tolerabilityand 1PK parameters of AB1003                                                                 | Double blind, placebo- controlled  | Capsule, ascending doses (40,100,200, 400 and 800 mg), oral              | 32                         | healthy volunteers                                                         | 7 days                        | Complete, Full                 |
| Type of study      | Study nunber      | Location in eCTD    | Objective(s) of the study                                                                                                   | Study Design and Type of Control   | Test product, dosage regimen,route of administration                     | Number of subjects         | Healthy subjects or diagnosis of patients                                  | Duration of treatment         | Study status, type of report   |
| PK/EfficacyAB03002 |                   | 5.3.3.2 and 5.3.5.2 | to assess safety /tolerability,PK parameters of AB1003, clinical activity of masitinib, to determine MTD                    | open-label, dose escalating study  | doses ranging from 40 to 1,000 mg/day                                    | 40 (with 19 GIST patients) | patients with advanced and/or metastatic solid tumors                      | 12 weeks + extension phase    | Complete, Full                 |
| Efficacy           | AB07001           | 5.3.5.1             | to assess the efficacy and safety of masitinib in GIST patients resistant toimatinib                                        | randomized, active- controlled     | Tablet, 12mg/kg/day, oral                                                | 44                         | patients with GIST resistant to imatinib                                   | Until progression             | Complete, Full                 |
| Efficacy           | AB04016           | 5.3.5.2             | to assess the efficacy and safety of masitinib in non-pretreated, inoperable patients with locally advanced/metastatic GIST | multicenter, single group          | Tablet, 7.5mg/kg/day, oral                                               | 30                         | non pre-treated, inoperable patients with locally advanced/metastatic GIST | 16 weeks + extension phase    | Complete, Full                 |

GIST

## 2.4.2. Pharmacokinetics

## Absorption

Following oral administration, masitinib was relatively slowly absorbed with Tmax values between 2-5 hrs. No absolute bioavailability studies have been performed.

## · Bioequivalence

Study AB1010-PIHV04015 evaluated the relative bioavailability of masitinib from two different formulations capsule used in phase I studies or tablet (the-to-be-marketed formulation) in 12 healthy male volunteers after a 100 mg masitinib base single oral administration.  This was a

<div style=\"page-break-after: always\"></div>

single centre, open, two-way cross-over study, in which twelve healthy male volunteers, aged 18 to 45 years, received a single oral dose of masitinib (100 mg) on Day 1 of each of both treatment periods (tablet=treatment A and capsule=treatment B), separated by at least a oneweek interval where no masitinib was taken in order to prevent any carry-over effect. The results are tabulated below.

Table 5 - Geometric mean and CV% pharmacokinetic parameters of AB1003 following single oral administration

|                          | N=12                     | (ng/mL)     | tmar # (b)   | tiag # (E)   | AUCo-t ）(h*ng/mL)   | AUCo-inf (h*ng/mL)   | t12 (b)   | Frel   |
|--------------------------|--------------------------|-------------|--------------|--------------|---------------------|----------------------|-----------|--------|
| Treat A                  | Geom. Mean               | 67.00       | 3.50         | 0.00         | 791                 | 977                  | 13.7      | 1.00   |
| (Tablet)                 | CV%                      | 57          | [1.50;6.00]  | [0.00;1.00]  | 49                  | 44                   | 17        | 27     |
| Treat B                  | Geom. Mean               | 65.88       | 4.00         | 0.00         | 748                 | 977                  | 15.5      |        |
| (Capsule)                | CV%                      | 41          | [1.50;6.00]  | [0.00;0.50]  | 39                  | 29                   | 27        |        |
| Analysis ofvariance      | Analysis ofvariance      | NS          | NS           | NS           | NS                  | NS                   |           |        |
| Point estimate           | Point estimate           | 1.02        |              |              | 1.06                | 1.00                 |           |        |
| [90%confidence interval] | [90%confidence interval] | [0.84;1.23] |              |              | [0.92;1.22]         | [0.87;1.15]          |           |        |

#median and[min-max]

NS: Not Significant (p&gt;0.05)

## · Influence of food

Study No. AB1010-PIVH05031 was a single centre, open, randomized, two-way cross-over study, in which 12 healthy male volunteers, aged 18 to 45 years, received a single oral administration of 200 mg AB1010 tablets during two treatment periods (fed conditions and fasted conditions as a high fat breakfast), separated by a two-week washout period. Thirteen (13) patients were initially randomized, but one patient withdrew from the study and was therefore not considered in the pharmacokinetic analysis.

Based on AUC0-∞, the mean relative bioavailability (Fed/Fasted) was 1.23, the associated interindividual variability, as expressed by the CV%, was quite low (16%). Cmax increased by 19%. Although the tmax for AB1003 was increased by 1 hour after a high fat breakfast, the difference was not statistically significant. There was also a slight increase in the extent of formation of AB3280 metabolite as illustrated by the increase of AUC0-t by 17%. Metabolite Cmax and tmax were not affected by concomitant food intake.

## Distribution

At 100 mg and 400 mg repeated doses of masitinib, volumes of distribution of 1935 L and 1043 L respectively were determined.

The binding of  14 C-masitinib was determined on human blood cells, human plasma proteins and isolated human plasma proteins (HSA, AAG, GG). The  14 C-masitinib concentrations used, 1003000 ng/mL, corresponds to a plasma concentration expected under therapeutically conditions. The binding to plasma proteins was 94 %. Binding to human serum albumin (HSA) was high, 91 %. A lower binding occurred on α1-acid-glycoprotein (AAG) and on gamma-globulin (GG), 74%

<div style=\"page-break-after: always\"></div>

and 46%, respectively.

## Elimination

## · Excretion

Steady state apparent oral clearance and renal clearance were between 0.7-1.4 L/min and 9-18 mL/min, respectively. Elimination half-life was around 16-18 hrs. No mass balance studies were performed. Urinary recovery rates were low with approximate recoveries of 1.5% of dose for masitinib and 6% for its primary metabolite, respectively.

## · Metabolism

From in vitro studies of human liver microsomes, three metabolites have been identified with the N-demethylated (AB3280) form clearly dominating quantitatively. Recombinant cDNA expression studies and studies in human liver microsomes, demonstrated that CYP3A4 almost solely catalyses the formation of the primary metabolite with possible minor contributions from CYP2C8.

## Dose proportionality and time dependencies

- Dose proportionality

The applicant presented data from the target population for a primary analysis of dose proportionality. The Applicant presented data for dose as well as for weight-adjusted dose.

Statistical inferences test are tabulated below:

Table 6 - Coefficient of correlation between Cmax or AUC and dose levels

|                     | All tested subjects (N = 28)*   | All tested subjects (N = 28)*   |
|---------------------|---------------------------------|---------------------------------|
|                     | AUC ng.h/mL                     | Cmax ng/mL                      |
| Dose (mg)           | 0.79                            | 0.79                            |
| dose/weight (mg/kg) | 0.80                            | 0.83                            |

*Excludingpatient6-05and 7-03

No adequate formal inference test has been provided. Additionally, analysis from healthy volunteer study clearly suggested a lack of dose-proportionality with exposures increasing more than expected: i.e. in study AB1010-PIHV03003, in the dose range 100 to 400 mg, mean Cmax increased in a ratio of 2.6 and 7.6 when dose increased in a ratio of 2 and 4, while the mean AUC0-τ increased in a ratio of 2.5 and 8.0 and mean Ctrough increased in a ratio of 2.4 and 7.6.

## · Time dependency

PK data from day 7 in the repeated-dose study in healthy volunteers were presented. The mean ratio of Cmax observed between Day 7 and Day 1 was 1.60, 1.54 and 2.09 following treatment with masitinib 100, 200 and 400 mg respectively. In addition the mean ratio of Ctrough was 2.31, 2.54 and 2.71 over this dose range.  No significant difference of ratio was elicited between the levels of dose. However it was observed that the ratio of Ctrough was statistically higher (p&lt;0.0001) than the theoretical ratio calculated from the terminal t1/2. In the dose

<div style=\"page-break-after: always\"></div>

range 100 to 400 mg, mean Cmax increased in a ratio of 2.6 and 7.6 when dose increased in a ratio of 2 and 4, while the mean AUC0-τ increased in a ratio of 2.5 and 8.0 and mean Ctrough increased in a ratio of 2.4 and 7.6.

## Special populations

No special population PK studies performed.

The applicant has stratified PK data from the target population with respect to gender and age.

## · Gender

Gender did not appear to influence Cmax and AUC of masitinib to a clinically relevant degree (data not shown).

- Elderly

This stratification does not allow for a meaningful assessment of the influence of age due to the small sample presented (data not shown).

- Weight

This stratification fails to support the weight-based posology as suggested by the Applicant. (data not shown).

## Pharmacokinetic interaction studies

In vitro studies were discussed in the nonclinical section.  No results from in vivo DDI studies have been provided since clinical studies are still on-going.

## 2.4.3. Pharmacodynamics

## Mechanism of action

The mechanism of action has been deducted from animal models and in vitro systems. Masitinib is a tyrosine kinase inhibitor with anti-tumoural and anti-inflammatory activity. Masitinib is an inhibitor of the KIT wild type (WT) receptor and its mutated forms (exon 9 and exon 11), as well as the platelet-derived growth factor alpha (PDGFRA) receptor.

Confirmation of the activity of masitinib in vivo was provided by xenograft studies in nude mice; orally administered masitinib reduces tumour volumes in a dose dependent manner in nude mice that were subcutaneously grafted with a transgenic murine hematopoietic cell line (BA/F3 c-Kit d27 model).

## Primary and Secondary pharmacology

No Primary and Secondary pharmacology studies have been submitted (see discussion on clinical pharmacology).

QTc intervals from study AB1010-PIHV03001 and study AB1010-PIHV03003 were presented.

<div style=\"page-break-after: always\"></div>

Given the in vitro data and data from other TKI's, prolongation of the QTc interval may be a clinically relevant issue. The data available from healthy volunteer studies were not entirely consistent, but there appeared to be a dose-related increase in QTc intervals that for the higher doses approach 20-30ms (data not shown).

## 2.4.4. Discussion on clinical pharmacology

The PK of masitinib has been investigated in 2 studies in healthy volunteers and in one study of target populations. Additionally, one BE study has been made to bridge PK data from the early formulation used to the to-be-marketed formulation. One study on food-interaction has also been conducted. There are no clinically relevant differences in PK parameters between healthy volunteers and those obtained in the target population.

The absorption profile of masitinib demonstrated a relatively slow absorption with Tmax values between 2 and 5 hours at suggested clinical doses. Bioequivalence has been adequately demonstrated for the to-be-marketed tablet formulation versus the formulation used in phase I.

Following a high fat meal, Cmax and AUC of masitinib increased by 19% and 23%, respectively. This is a moderate order of magnitude and appeared unlikely to be of clinical relevance.

The PK of masitinib has not been studied in any special populations. The Applicant has only stratified according to gender and age based on limited data and therefore few conclusions can be drawn. Gender does not appear to influence PK of masitinib to a clinically meaningful degree. The amount of data does not allow for estimation of the possible influence of age. There are no data on renal or hepatic impairment.

In vitro data suggested that there be a number of clinically relevant drug-drug interactions. Further investigation would be required.

No specific studies on primary and secondary pharmacology have been performed.

QTc intervals from study AB1010-PIHV03001 and study AB1010-PIHV03003 were presented. Given the in vitro data and data from other TKIs, prolongation of the QTc interval may be a clinically relevant issue. The data available from healthy volunteer studies were not entirely consistent, but there appeared to be a dose-related increase in QTc intervals that for the higher doses approach 20-30ms. In the healthy volunteer study (AB03003), observed QT increases were subsequently considered to be normal following a re-reading of the electrocardiograms (ECGs). The descriptive narratives of the patients who experienced cardiac events did not provide clear evidence of an effect of masitinib on the QT/QTc interval. However, an effect of masitinib on QTc cannot be ruled out. The clinical evaluation of QT/QTs interval prolongation and pro-arrhythmic potential for non-anti-arrhythmic drugs would be required to address whether masitinib has the potential to induce QTc interval prolongation.

## 2.4.5. Conclusions on clinical pharmacology

Overall, the PK of masitinib would require further investigation. Additional studies in special populations, on drug-drug interactions and a thorough QT/QTc study are also needed.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

Early dose finding studies were:

- Study AB1010-PIHV03001 - A phase I, double blind, placebo-controlled study to determine the safety, tolerability and PK profiles of ascending, single oral doses of AB1010 in healthy, young male subjects
- Study AB1010-PIHV03003 - A phase I, double blind, placebo-controlled study to determine the safety, tolerability and PK profiles of ascending, multiple oral doses of AB1010 in healthy, young male subjects.

Dose response studies were:

- Study No AB1010 PIST 03002 - A phase I, open-label, dose escalating study of oral AB1010 in patients with solid tumours
- Study AB04016 - Phase II study of oral AB1010 in non-pretreated, inoperable patients with locally advanced/metastatic gastro-intestinal stromal tumour (GIST)

The selection of the 12 mg/kg/day dose for future studies in second line therapy for GIST is based on the efficacy and safety results in 10/19 patients with GIST in the phase I/II study AB03002 in which 4 dose levels (&lt; 3 mg/kg/day; 7.5 mg/kg/day; 12 mg/kg/day, and 15 mg/kg/day) were investigated.

In this phase I dose-escalating study, 40 patients with advanced and/or metastatic cancer including 19 patients with GIST, were enrolled. This study aimed to determine the maximum tolerated dose (MTD) for orally administered masitinib over a 12-week period. Secondary objectives were clinical assessment of masitinib activity in cancer patients and establishment of the pharmacokinetic profile.

Among the 19 GIST patients included in this study, all were considered as imatinib-resistant: 15/19 (78.9%) were resistant to 800 mg/day as maximal prior imatinib dose received, 3/19 (15.8%) were noted by the investigator as resistant to 400 mg/day, and for one (5.3%) patient the dose of imatinib resistance was not collected.

In this study, most patients were in end-stage disease. This is reflected by a higher number of lines of treatment undergone by patients before study enrollment, and by a greater proportion of patients having a worse Eastern Cooperative Oncology Group (ECOG) performance status (i.e. an ECOG value of 1) compared with study AB07001.

No mutational analysis was performed on patients in the phase I AB03002 study and therefore the c-Kit and PDGFR mutational status is unknown.

The 19 GIST patients received masitinib doses ranging from 0.7 to 17.2 mg/kg/day:

-Three patients received low masitinib doses ranging from 0.7 to 2.1 mg/kg/day. These patients will be referred to as the '&lt; 3 mg/kg/day' cohort.

<div style=\"page-break-after: always\"></div>

- -Two patients received masitinib doses around 7.5 mg/kg/day, the dose used in first-line treatment for GIST (doses of 6.8 and 8.5 mg/kg/day, respectively). These patients will be referred to as the '7.5 mg/kg/day' cohort.
- -Ten patients received masitinib doses around 12 mg/kg/day, the dose used in secondline treatment for GIST (dose range of 10.8 to 13.0 mg/kg/day). These patients will be referred to as the '12 mg/kg/day' cohort.
- -Four patients received masitinib doses around 15 mg/kg/day (dose range of 15.1 to 17.2 mg/kg/day). These four patients will be referred to as the '15 mg/kg/day' cohort.

Patients from the '&lt; 3 mg/kg/day' cohort received doses lower than 3 mg/kg/day which are too far from the 12 mg/kg/day target dose used in treatment of GIST patients resistant to imatinib. These patients  were therefore of little relevance for efficacy analysis. The dose of 15 mg/kg/day was identified as the toxicity limiting dose from which gastrointestinal adverse events including vomiting were more frequently reported.

Hence, efficacy analysis was performed on the study's overall GIST population of 19 patients, and also on the 12 patients with the appropriate dose regimen, i.e. the two patients from the '7.5 mg/kg/day' cohort, and the ten patients from the '12 mg/kg/day cohort'. This latter group of patients is hereafter referred to as the 'selected GIST cohort'.

Evaluation of PFS in all 19 GIST patients included in the study revealed that median PFS was 1.8 months (95% CI [1.3; 3.0]) with PFS rates at 6, 12 and 18 months of treatment of 20.5%, 6.8% and 6.8%, respectively.

PFS analysis in the selected GIST cohort showed that median PFS was 2.5 months (95% CI [1.4; 6.5]) with PFS rates at 6, 12 and 18 months of treatment of 28.6%, 9.5% and 9.5%, respectively.

## 2.5.2. Main studies

## Study AB07001

## Methods

Study AB07001 is a prospective, multicentre, randomised, open-label, active-controlled, 2parallel group, Phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumour resistant to imatinib.

## Study Participants

Inclusion criteria consisted of:

- Men or women, age &gt;18 years
- Histological proven, metastatic, or locally advanced and non-operable GIST
- Measurable tumour lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST criteria
- KIT (CD117) positive tumours detected immunohistochemical and documented mutation of c-Kit at any time if available
- Patients resistant to imatinib at the dose of 400 mg/day.

<div style=\"page-break-after: always\"></div>

- ECOG ≤ 2
- Patient with adequate organ function
- Patient with life expectancy &gt; 6 months

Amongst exclusion criteria were:

- Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ.
- Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis.
- Patient presenting with defined cardiac disorders.

## Treatments

Subjects were randomised 1:1 to treatment Group 1 or Group 2:

- Group 1 - Oral masitinib, to be taken twice daily during meals. Each tablet contained 100 mg or 200 mg. Patients received an initial starting daily dose of 12 mg/kg/day.
- Group  2 -  50  mg/day  sunitinib  once  daily  for  4  consecutive  weeks  out  of  every  6  weeks (Group  2).  Dose  escalation  was  not  allowed  during  the  study  (any  dose  escalation  was considered as progression).

## Objectives

The objectives of this randomized, open-label, parallel-group study were to assess the efficacy and safety of masitinib in GIST patients under progression with imatinib.

## Outcomes/endpoints

The primary endpoint was progression-free survival (PFS) measured from the date of randomization to the date of documented progression according to RECIST or death.

Secondary endpoints included:

- Overall Survival (OS) and Overall Time to progression (TTP)
- Objective response rate (CR + PR) and the Disease Control rate measured at weeks 8, 16, 24, 36 and after Week 36 and the best response (CR or PR or SD or PD) during the study.
- PFS analysis according to different assessment criteria for progression: 1/ according to the investigator,  2/  according  to  RECIST  and  centrally  reviewed  by  an  independent  response review  committee,  3/  according  to  CHOI  centrally  reviewed  by  an  independent  response review  committee  and  4/  according  to  Time  to  Treatment  Failure,  defined  as  the  time between randomization and switch to post-study or death, whichever occurred first.
- Correlation  between  PFS,  OS,  TTP,  objective  response,  control  disease  rate  and  the phenotype of mutations on c-Kit/PDGF
- Quality  of  life  according  to  the  EORTC  QLQ-C30  questionnaire,  the  Karnofsky  Performance Status, and the ECOG Performance Status at weeks 8, 16, 24, 36 and after Week 36.

PFS, OS, TTP, objective response rate and disease control rate, and best response were assessed by CT scan according to RECIST 1.1 criteria.

<div style=\"page-break-after: always\"></div>

## Sample size

Hypotheses for sample size calculation were the same for the two treatment groups, masitinib and sunitinib:

- Duration of accrual period: 24 months
- Duration of follow-up period-time from end of accrual to analysis: 6 months
- Alpha set to 0.10
- Power set to 0.8
- One-sided test
- The median survival time for the null and alternative hypotheses were respectively 3 months (largest PFS that implied that masitinib was not to be chosen for further studies) and 5 months (smallest PFS that implied that masitinib was to be chosen for further studies)
- PFS was assumed to be exponentially distributed

19 patients were necessary in each treatment group with the following hypotheses:

- H0: median PFS &lt; 3 months
- HA: median PFS &gt; 5 months

38 PP patients were necessary to achieve this study. The number of patients required was 44 patients (22 per group) in order to take into account major protocol deviations or early dropouts (estimated rate around 15%).

## Randomisation

Subjects were randomised in a 1:1 ratio. Treatment group was to be allocated according to a modified minimization method (random assignment) which allows for reducing the differences in size between the two treatment groups within the different strata of KIT mutation (exon 9 exon 11 other).

## Blinding (masking)

Not applicable.

## Statistical methods

As stated in the study protocol, from a statistical point of view this study was not designed as a comparative study between masitinib and sunitinib, so comparison of confidence intervals between groups were to be exploratory.

The Initial Hypothesis was:

- 'H0: median PFS &lt; 3 months, HA: median PFS &gt; 5 months'. This test is conclusive if the lower bound of the 90% one-sided confidence interval is greater than 3 months (H0 hypothesis rejected) and greater than 4.12 months (HA hypothesis fulfilled).

- This hypothesis was based upon historical data from the sunitinib phase II/III study [Demetri, 2006; Seddon, 2008; Morgan, 2006].

The Hypothesis has been revised as follows:

<div style=\"page-break-after: always\"></div>

- 'H0: median PFS &lt; 3 months, HA: median PFS &gt; 3 months'. This test is conclusive if the lower bound of the 90% one-sided confidence interval is greater than 3 months (H0 hypothesis rejected and HA hypothesis fulfilled).

- This revised hypothesis was proposed by experts of the data review committee held in December 2011 before database lock.

The main analysis was conducted with a data cut-off fixed on January 31st 2012.

Intent to Treat (ITT) population: composed of all included patients, whether they have received the study treatment or not. The documented lack to take at least one dose of the study drug and patients with no efficacy measure after first treatment intake was discussed on a case-bycase basis.

Modified Intent-to-treat population (mITT): all ITT patients but excludes the patients that exited the study prematurely for well-documented non treatment-related cause.

Per Protocol (PP) population: The PP dataset consists of all patients of the ITT dataset without any major protocol deviations. Patients terminating the study prematurely were included in the PP dataset provided that there was no protocol deviation.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

## Recruitment

This study AB07001 was carried out in 9 centres in France.

## Conduct of the study

The study was initiated in February 2009 and the cut-off date was 31st January 2012.

## Baseline data

Demographics and baseline characteristics are summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 7 - Patient demographics and baseline characteristics, ITT population

|                      | MASITINIB (N=23)   | SUNTTINIB (N=21)   | p-ralue   |
|----------------------|--------------------|--------------------|-----------|
| Ser                  |                    |                    | 1.000 (F) |
| Male                 | 11 (47.8%)         | 11 (52.4%)         |           |
| Female               | 12 (52.2%)         | 10 (47.6%)         |           |
| Age (years)          |                    |                    | 0.424 (W) |
| Mean ± Std           | 62.1 ± 15.1        | 66.7 ± 12.3        |           |
| Median               | 64.0               | 67.0               |           |
| Range                | 31.0 -82.0         | 41.0 - 85.0        |           |
| Age class            |                    |                    | 0.563 (F) |
| ≤ 65-year old        | 12 (52.2%)         | 9 (42.9%)          |           |
| > 65-year old        | 11 (47.8%)         | 12 (57.1%)         |           |
| Baveline weight (lg) |                    |                    | 0.306 (W) |
| Mean ± Std           | 64.9 ± 14.6        | 69.2 ± 12.6        |           |
| Median               | 62.0               | 73.0               |           |
| Range                | 44.0: 90.5         | 42.0:88.0          |           |
| Weight2 60 kg        | 14 (60.9%)         | 17 (81.0%)         | 0.194 (F) |

(W) Wilcoron test; (F) Fisher's eract test

At the time of first diagnosis, localization of primary tumours was mainly intestinal (47.8% of masitinib-treated patients and 52.4% of sunitinib-treated patients), and gastro-oesophageal (34.8% and 28.6% of masitinib- and sunitinib-treated patients, respectively). No significant difference was observed between the two treatment arms.

Tumour classification was equally distributed between patients of both groups, most of them with metastatic tumours. In particular among masitinib-treated patients, 2 (8.7%) had locally advanced tumours, and 21 (91.3%) patients had metastases. In sunitinib-treated patients, 3 (14.3%) had locally advanced tumours, and 18 (85.7%) had metastases.

Biopsies of the tumours were taken in patients prior to the beginning of the treatment and KIT and PDGFR mutational status are summarized below.

Table 8 - KIT mutation analysis

|                         | MASITINIB (N=23)   | SUNITINIB (N=21)   | p-value   |
|-------------------------|--------------------|--------------------|-----------|
| KIT positive expression | 23 (100.0%)        | 21 (100.0%)        |           |
| Exon Mutation           |                    |                    | 1.000 (F) |
| N                       | 19                 | 17                 |           |
| Nomutation              | 1 (5.3%)           |                    |           |
| Exon 9                  | 3 (15.8%)          | 2 (11.8%)          |           |
| Exon 11                 | 15 (78.9%)         | 14 (82.4%)         |           |
| Exon11+Exon17           | 1 (5.3%)           | 1 (5.9%)           |           |
| Exon 13                 |                    | 1 (5.9%)           |           |
| PDGFR expression        |                    |                    |           |
| Positive                | 3 (13.0%)          | 3 (14.3%)          |           |
| Negative                | 3 (13.0%)          | 5 (23.8%)          |           |
| Unknown                 | 17 (73.9%)         | 13 (61.9%)         |           |

(F)Fisher's exact test

Among previous therapies for GIST, most patients (91.3% of masitinib-treated patients and 85.7% of sunitinib-treated patients) experienced surgery resections. Tumourectomy in particular was experienced in 52.2% of masitinib-treated patients, and in 66.7% of sunitinib-treated patients.

<div style=\"page-break-after: always\"></div>

56.5% and 42.9% of patients aimed to receive masitinib and sunitinib respectively, experienced other surgeries for their GIST.

None of the sunitinib-treated patients had radiotherapy for their GIST, while only one patient receiving masitinib experienced previous and curative radiotherapy.

All patients included in the study previously received imatinib and had to be resistant to imatinib at the dose of 400 mg. The table below describes the highest previous imatinib dose received by patients of each treatment arm before entering the study, as well as the duration of this treatment.

Table 9 - Previous treatment with imatinib

| Number (%) of patients with                                      | MASITINIB (N=23)   | SUNITINIB (N=21)   | p-value   |
|------------------------------------------------------------------|--------------------|--------------------|-----------|
| Lastimatinibtreatmentterminationbecauseoflackofefficacy          | 23 (100.0%)        | 21 (100.0%)        |           |
| Last imatinib treatment: Progression within 6months withimatinib | 3 (13.0%)          | 4 (19.0%)          | 0.693 (F) |
| Maximalprevious doseofimatinib                                   |                    |                    | 0.494 (F) |
| 400 mg/day                                                       | 16 (69.6%)         | 17 (81.0%)         |           |
| 800 mg/day after progression with 400 mg/day                     | 7 (30.4%)          | 4 (19.0%)          |           |
| Cumulative duration (months)                                     |                    |                    | 0.707 (W) |
| Mean ± Std                                                       | 41.4±26.8          | 45.9 ±38.1         |           |
| Median                                                           | 32.7               | 28.2               |           |
| Min; Max                                                         | 8.8; 103.3         | 5.4; 114.3         |           |
| Cumulative duration - N (%)                                      |                    |                    |           |
| > 24 months                                                      | 17 (73.9%)         | 11 (52.4%)         | 0.211 (F) |
| >36 months                                                       | 9 (39.1%)          | 7 (33.3%)          | 0.761 (F) |

(F) Fisher's exact test; (W) Wilcoxon test

## Numbers analysed

23 subjects were randomised to masitinib and 21 subjects were randomised to sunitinib. Fortyfour patients were included in the ITT and SAF population.. One patient was excluded from the PP population (43 patients).

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Primary Endpoint - PFS according to central RECIST

Table 10. Summary of PFS central RECIST analyses and results from statistical tests according to the ITT population - Cut-off date: 31 January 2012

|                                                  | MedianPFSin months [95%two-sidedC1] (lowerbound90% one-sided CI)   | Patients censored n (%)   | Firsttestconclusive(Yes/No) H0:medianPFS<3M HA:medianPFS>5M Test conclusive ifCIlowerbound>4.12M   | Firsttestconclusive(Yes/No) H0:medianPFS<3M HA:medianPFS>5M Test conclusive ifCIlowerbound>4.12M   | Second testconclusive(Yes/No） H0:medianPFS<3M HA:medianPFS>3M Testconclusive ifCIlowerbound>3M   | Second testconclusive(Yes/No） H0:medianPFS<3M HA:medianPFS>3M Testconclusive ifCIlowerbound>3M   |
|--------------------------------------------------|--------------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Progression-FreeSurvivalaccordingtocentralRECIST |                                                                    |                           |                                                                                                    |                                                                                                    |                                                                                                  |                                                                                                  |
| Methodofcensoring-asperprotocol MASITINIB (N=23) | 3.7 [1.9; 6.0] (3.7)                                               | 5 (22%) 3 (14%)           | Two-sided 95%One-sided90% No No Two-sided95%One-sided90%                                           | No No                                                                                              | 6Two-sided95%One-sided90% No                                                                     | Yes No                                                                                           |
| SUNITINIB (N=21)                                 | 1.9 [1.8; 4.4] (1.9)                                               |                           |                                                                                                    |                                                                                                    | No                                                                                               |                                                                                                  |
| Methodofcensoring-analysis#1 MASITINIB (N=23)    | 3.7 [2.0:6.0](3.7)                                                 | 2 (8.7%)                  | No No                                                                                              | No No                                                                                              | Two-sided95%One-sided90% No                                                                      | Yes No                                                                                           |
| SUNITINIB (N=21)                                 | 1.9 [1.8:4.4 ] (1.9)                                               | 3 (14%)                   |                                                                                                    |                                                                                                    | No                                                                                               |                                                                                                  |
| Methodofcensoring-analysis#2 MASITINIB (N=23)    | 3.7 [2.0; 8.8 ] (3.7)                                              | 5 (22%)                   | Two-sided95%One-sided90% No                                                                        | No                                                                                                 | Two-sided95%One-sided90% No                                                                      | Yes                                                                                              |
| SUNITINIB (N=21)                                 | 1.9 [1.8; 4.4 ] (1.9)                                              | 3 (14%)                   | No                                                                                                 | No                                                                                                 | No                                                                                               | No                                                                                               |

## Secondary Endpoints and Outcomes

- Overall Survival (OS) - 31 January 2012

At the time of cut-off date, median follow-up for OS was 14 months in the masitinib arm and 15 months in the sunitinib. OS was increased in the masitinib arm, with a median OS estimated to be higher than 21.2 months (95% CI [21.2; NA]) as compared with a median OS of 15.2 months in sunitinib arm (95% CI [9.4; 21.7]). The estimated HR was 0.29 [0.10; 0.85] (p-value=0.016) (Figure 1).

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Figure 1 - Kaplan-Meier OS analysis - Overall population - Study AB07001

- Progression Free Survival (PFS) - 31 January 2012

Results of the primary analysis based upon the primary endpoint PFS according to RECIST criteria centrally reviewed, are presented in the table and figure below.

Table 11 - PFS according to RECIST

|                                                            |    | Median PFS (months) [95% CI] bound one-sided CI)   | PFS rates over time (% [95% CI])   | PFS rates over time (% [95% CI])   |
|------------------------------------------------------------|----|----------------------------------------------------|------------------------------------|------------------------------------|
| PFS according to centralized RECIST                        | N  | (lower 90%                                         | Month 6                            | Month 12                           |
| Overall population                                         |    |                                                    |                                    |                                    |
| Method of censoring - as per protocol                      |    |                                                    |                                    |                                    |
| MASITINIB                                                  | 23 | 3.7 [1.9; 6.0] (3.7)                               | 34.7 [14.7; 55.6]                  | 7.7 [0.6; 28.2]                    |
| SUNITINIB                                                  | 21 | 1.9 [1.8; 4.4] (1.9)                               | 23.8 [8.7; 43.1]                   | 23.8 [8.7; 43.1]                   |
| log-rank p-value*                                          |    | 0.833                                              |                                    |                                    |
| Hazard ratio for progression [95% CI]*                     |    | 1.07 [0.54 ; 2.13]                                 |                                    |                                    |
| KIT Exon 11 mutation Method of censoring - as per protocol |    |                                                    |                                    |                                    |
| MASITINIB                                                  | 15 | 2.0 [1.7; 6.0] (1.8)                               | 29.1 [7.5; 55.5]                   | 9.7 [0.6; 34.7]                    |
| SUNITINIB                                                  | 14 | 1.9 [1.1; 4.4] (1.8)                               | 21.4 [5.2; 44.8]                   | 21.4 [5.2; 44.8]                   |
| log-rank p-value                                           |    | 0.751                                              |                                    |                                    |
| Hazard ratio for progression [95% CI]                      |    | 1.14 [0.50; 2.61]                                  |                                    |                                    |
| KIT Exon 9 mutation                                        |    |                                                    |                                    |                                    |
| MASITINIB                                                  | 3  | 3.8 [1.2; NA] (1.3)                                | 33.3 [0.9; 77.4]                   | NR                                 |
| SUNITINIB                                                  | 2  | 3.0 [1.0; 5.1] (1.0)                               | 0.0                                | 0.0                                |
| log-rank p-value                                           |    | 0.586                                              |                                    |                                    |
| Hazard ratio for progression [95% CI]                      |    | 0.58 [0.08; 4.26]                                  |                                    |                                    |
| Imatinib 400 mg                                            |    |                                                    |                                    |                                    |
| Method of censoring - as per protocol                      |    |                                                    |                                    |                                    |
| MASITINIB                                                  | 16 | 3.7 [3.6; 6.2] (3.7)                               | 40.6 [15.3; 64.9]                  | 12.2 [0.9; 39.0]                   |
| SUNITINIB                                                  | 17 | 3.5 [1.8; 5.1] (1.9)                               | 23.5 [7.3; 44.9]                   | 23.5 [7.3; 44.9]                   |
| log-rank p-value*                                          |    | 0.953                                              |                                    |                                    |
| Hazard ratio for progression [95% CI]*                     |    | 1.02 [0.46; 2.26]                                  |                                    |                                    |
| Imatinib 800 mg                                            |    |                                                    |                                    |                                    |
| MASITINIB                                                  | 7  | 1.7 [1.1; 9.9] (1.2)                               | 21.4 [1.2; 58.6]                   | 0.0                                |
| SUNITINIB                                                  | 4  | 1.4 [1.0; NA] (1.0)                                | 25.0 [0.9; 66.5]                   | 25.0 [0.9; 66.5]                   |
| log-rank p-value*                                          |    | 0.625                                              |                                    |                                    |
| Hazard ratio for progression [95% CI]*                     |    | 0.68 [0.15; 3.18]                                  |                                    |                                    |

NR: not reached; NA: not assessable

<div style=\"page-break-after: always\"></div>

Figure 2 - Kaplan-Meier PFS analysis according to RECIST - Overall population

<!-- image -->

| Number of patients at risk at   |   Month 3 |   Month 6 |   Month 9 |   Month 12 |   Month 15 |   Month 18 |
|---------------------------------|-----------|-----------|-----------|------------|------------|------------|
| MASITINIB                       |        12 |         6 |         2 |          1 |          0 |          0 |
| SUNITINIB                       |        10 |         5 |         4 |          4 |          0 |          0 |

- Tumour response assessment and best response during the study

Tumour assessment was performed on CT scan evaluations according to RECIST criteria and investigator's decision. Responses during the study were performed without and with confirmation RECIST criteria. Results are presented in the table below.

Table 10 - Response during the study - Assessment according to RECIST

| Nunber (%) of patients with                                                   | MASITINIB (N=23)        | SUNITINIB (N=21)        | p-value    |
|-------------------------------------------------------------------------------|-------------------------|-------------------------|------------|
| Withoutconfirmationcriteria                                                   |                         |                         |            |
| Best response during the study                                                |                         |                         | 0.813 (MH) |
| Complete response (CR)                                                        |                         |                         |            |
| Partial response (PR)                                                         | 1 (4.3%)                | 2 (9.5%)                |            |
| Stable disease (SD)                                                           | 18 (78.3%)              | 15 (71.4%)              |            |
| Progressive disease (PD)                                                      | 4 (17.4%)               | 4 (19.0%)               |            |
| Disease control rate (CR +PR+SD) [95% CI]                                     | 19 (82.6% [62.9;93.0])  | 17 (81.0% [60.0; 92.3]) | 1.000 (F)  |
| Objective Response Rate (CR+PR) [95% CI]                                      | 1 (4.3% [0.8; 21.0])    | 2 (9.5% [2.7; 28.9])    | 0.599 (F)  |
| With confirmation criteria                                                    |                         |                         |            |
| Disease control rate (CR +PR+SD) [95% CI]                                     | 17 (73.9% [53.5; 87.5]) | 14 (66.7% [45.4; 82.8]) | 0.744 (F)  |
| Objective Response Rate (CR+PR) [95% CI]                                      | 1 (4.3% [0.8; 21.0])    | 1 (4.8% [0.8; 22.7])    | 1.000 (F)  |
| Clinical benefit [95% C1] (confirmed PR 4 weeks or CR 4 weeks or SD 16 weeks) | 6 (26.1% [12.5; 46.5])  | 6 (28.6% [13.8; 50.0])  | 1.000 (F)  |

<div style=\"page-break-after: always\"></div>

## · Quality of Life

QoL response was defined as improvement (&gt; 10 points), stable or worsening (&lt; 10 points), based on Global health status scale of EORTC QLQ-C30 questionnaire. Assessment of quality of life response was available for 15 (75.0%) subjects in the masitinib arm and 13 (65.0%) subjects in the sunitinib arm.

Table 11 - QoL response during the study

|                                    | MASITINIB (N=23)   | SUNITINIB (N=21)   | p-value    |
|------------------------------------|--------------------|--------------------|------------|
| Assessmentavailableatbaseline      | 20 (87.0%)         | 20 (95.2%)         |            |
| Assessment post baseline available | 15 (75.0%)         | 13 (65.0%)         |            |
| QoLresponse                        |                    |                    | 0.378 (MH) |
| N                                  | 15                 | 13                 |            |
| Improvement                        | 2 (13.3%)          | 3 (23.1%)          |            |
| Stable                             | 9 (60.0%)          | 2 (15.4%)          |            |
| Worsening                          | 4 (26.7%)          | 8 (61.5%)          |            |
| QoLresponse                        |                    |                    | 0.063 (F)  |
| N                                  | 15                 | 13                 |            |
| Improvement or stable              | 11 (73.3%)         | 5 (38.5%)          |            |
| Worsening                          | 4 (26.7%)          | 8 (61.5%)          |            |

(MH) Mantel-Haenszel Chi-square test; (F) Fisher's exact test

## Ancillary analyses

Not applicable

## Summary of main study

The following tables summarise the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 12 - Summary of Efficacy for trial AB07001

| Title : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, Phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib   | Title : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, Phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib   | Title : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, Phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib   | Title : A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, Phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                            | Study AB07001 EUDRACT number: 2007-005889-12                                                                                                                                                                                                                                                | Study AB07001 EUDRACT number: 2007-005889-12                                                                                                                                                                                                                                                | Study AB07001 EUDRACT number: 2007-005889-12                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                      | Prospective, multicenter, randomized, open-label, active-controlled, 2- parallel group, Phase II study                                                                                                                                                                                      | Prospective, multicenter, randomized, open-label, active-controlled, 2- parallel group, Phase II study                                                                                                                                                                                      | Prospective, multicenter, randomized, open-label, active-controlled, 2- parallel group, Phase II study                                                                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                                                  | Exploratory                                                                                                                                                                                                                                                                                 | Exploratory                                                                                                                                                                                                                                                                                 | Exploratory                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                                                                                                           | Group 1                                                                                                                                                                                                                                                                                     | Group 1                                                                                                                                                                                                                                                                                     | 22 patients were to receive masitinib at 12 mg/kg/day, until disease progression                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                           | Group 2                                                                                                                                                                                                                                                                                     | Group 2                                                                                                                                                                                                                                                                                     | 22 patients were to receive sunitinib at 50 mg/day for 4 consecutive weeks out of every 6 weeks until disease progression                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                                                                                                            | PFS                                                                                                                                                                                                                                                                                         | Progression Free Survival according to RECIST criteria centrally reviewed                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|               | Secondary endpoint   | OS   | Overall survival   |
|---------------|----------------------|------|--------------------|
| Database lock | 31 January 2012      |      |                    |

## Results and Analysis

| Analysis description                            | Primary Analysis                                                                                                                                                    | Primary Analysis                                                                                                                                                    | Primary Analysis                                                                                                                                                    |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat                                                                                                                                                     | Intent to treat                                                                                                                                                     | Intent to treat                                                                                                                                                     |
| Descriptive statistics and estimate variability | Progression Free Survival according to RECIST criteria based on central review. Lower bound of the 90% one-sided confidence interval greater than 3 months.         | Progression Free Survival according to RECIST criteria based on central review. Lower bound of the 90% one-sided confidence interval greater than 3 months.         | Progression Free Survival according to RECIST criteria based on central review. Lower bound of the 90% one-sided confidence interval greater than 3 months.         |
| PFS (median, months)                            | 3.7 months in the masitinib treatment-arm with a lower bound of the 90% unilateral confidence interval being 3.7 (greater than the tested lower bound of 3 months). | 3.7 months in the masitinib treatment-arm with a lower bound of the 90% unilateral confidence interval being 3.7 (greater than the tested lower bound of 3 months). | 3.7 months in the masitinib treatment-arm with a lower bound of the 90% unilateral confidence interval being 3.7 (greater than the tested lower bound of 3 months). |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                     | Masitinib                                                                                                                                                           | Sunitinib                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subject PFS (median, months)                                                                                                                              | 23                                                                                                                                                                  | 21                                                                                                                                                                  |
| Descriptive statistics and estimate variability |                                                                                                                                                                     | 3.7                                                                                                                                                                 | 3.8                                                                                                                                                                 |
| Descriptive statistics and estimate variability | 95% CI OS                                                                                                                                                           | 2.6-6.2                                                                                                                                                             | 1.9-4.4                                                                                                                                                             |
| Descriptive statistics and estimate variability | (median, months)                                                                                                                                                    | 21.2                                                                                                                                                                | 15.2                                                                                                                                                                |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                              | 21.2-NA                                                                                                                                                             | 9.4-21.7                                                                                                                                                            |
| Effect estimate per comparison                  | Primary endpoint PFS                                                                                                                                                | Comparison groups                                                                                                                                                   | Masitinib vs Sunitinib                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                     | HR                                                                                                                                                                  | 0.98                                                                                                                                                                |
| Effect estimate per comparison                  |                                                                                                                                                                     | 95% CI                                                                                                                                                              | 0.49-1.98                                                                                                                                                           |
| Effect estimate per comparison                  |                                                                                                                                                                     | P-value                                                                                                                                                             | 0.964                                                                                                                                                               |
| Effect estimate per comparison                  | Secondary endpoint OS                                                                                                                                               | Comparison groups                                                                                                                                                   | Masitinib vs Sunitinib                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                     | HR                                                                                                                                                                  | 0.29                                                                                                                                                                |
| Effect estimate per comparison                  |                                                                                                                                                                     | 95% CI                                                                                                                                                              | 0.10-0.85                                                                                                                                                           |
| Effect estimate per comparison                  |                                                                                                                                                                     | P-value                                                                                                                                                             | 0.016                                                                                                                                                               |

CI: confidence interval; HR: hazard ratio; NA: not assessable

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

No studies in patients with hepatic or renal impairment have been submitted.

## Supportive studies

## Study AB03002

In  this  phase  I  dose-escalating  study,  40  patients  with  advanced  and/or  metastatic  cancer including 19 patients with GIST, were enrolled. This study aimed to determine the MTD for orally

<div style=\"page-break-after: always\"></div>

administered masitinib over a 12-week period. Secondary objectives were clinical assessment of masitinib activity in cancer patients and establishment of the pharmacokinetic profile.

Primary  endpoint:  The  dose  determined  to  be  used  for  future  phase  II  studies  was  12 mg/kg/day.

Secondary endpoints: Evaluation of PFS in the subgroup of patients included in the study with GIST revealed that median PFS was 1.8 months (95% CI [1.3; 3.0]) with PFS rates at 6, 12 and 18 months of treatment of 20.5%, 6.8% and 6.8%, respectively.

The 'selected GIST patients' consisted of the GIST patients included in the phase I study that were treated with masitinib with dose ranging from 7.5 mg/kg/day to 12 mg/kg/day (excluding the patients that were treated with lower or higher doses of masitinib).

PFS analysis in the selected GIST cohort showed that median PFS was 2.5 months (95% CI [1.4; 6.5])  with  PFS  rates  at  6,  12  and  18  months  of  treatment  of  28.6%,  9.5%  and  9.5%, respectively.

The 19 GIST patients were followed for overall survival for a median of 72.9 months, and showed a median OS of 12.4 months (95% CI [7.3; 26.8]) with OS rates at 1, 2, 3, 4, and 5 years of 52.6%, 36.8%, 15.8%, 10.5%, and 5.3%, respectively.

OS analysis  in  the  selected  GIST  cohort  revealed  that  median  OS  was  23.4  months  (95%  CI [12.4; 34.4]) with OS rates at 1, 2, 3, 4, and 5 years of 75.0%, 50.0%, 25.0%, 16.7%, and 8.3%, respectively.

## Study AB04016

The supportive study AB04016 was a phase II study in 30 non-pretreated, inoperable patients with locally advanced/metastatic GIST and with an ECOG PS of 0-2. Masitinib was administered at 7.5 mg/kg/day.

Major efficacy endpoints were objective response rate, PFS, OS, and metabolic response rate.

Best  response  analysis  showed  that  four  patients  (13.3%)  had  a  complete  response  (CR),  13 patients (43.3%) had a partial response (PR), 12 patients (40.0%) had stable disease (SD), and one patient (3.3%) had progressive disease (PD).

Metabolic response was assessed by FDG-PET: At 2 months 3 patients (21.4%) had a complete metabolic  response  (CMR)  and  9  patients  (64.3%)  had  a  partial  metabolic  response.  Two patients (14.3%) had stable metabolic response. The overall metabolic response rate was 85.7% (95% CI [57.2; 98.2]) at 2 months.

The median PFS was 41.3 months (95% CI [17.5; 53.8]) and PFS rates were 77.3%, 61.0%, 57.0%, and 32.0%, after 1, 2, 3, and 4 years of treatment, respectively.

With a median follow-up of 65 months in patients with GIST and receiving masitinib as first-line treatment,  the  median  OS  in  study  AB04016  was  not  reached  (estimated  as  higher  than  53 months), with survival rates of 96.7%, 90.0%, 86.5%, 76.2%, 61.5%, and 55.9%  at 1, 2, 3, 4, 5 and 6 years, respectively.

<div style=\"page-break-after: always\"></div>

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This  application  for  marketing  authorisation  is  supported  by  the  phase  II  study  AB07001,  the supportive phase I study AB03002 and the supportive phase II study AB04016. Study AB07001 was planned only as an exploratory trial to determine whether it was worthwhile investigating masitinib  further.  The  study  was  not  planned  to  provide  statistical  comparisons  between masitinib  and  sunitinib.  The  overall  design  of  the  study  is  acceptable  for  an  exploratory  trial. However,  a  GCP  inspection  of  the  sponsor  site  and  of  two  clinical  trial  sites  of  pivotal  trial AB07001 revealed numerous critical and major findings related to the conduct of the study and collection of efficacy and safety data, including poor adherence to scheduling of visits to assess PFS.  The  Applicant  has  responded  to  the  numerous  GCP  inspection  findings  with  corrective measures whenever possible.

## Efficacy data and additional analyses

The primary endpoint of study AB07001 was PFS. This is an acceptable primary endpoint and the concept  of  utilising  PFS  in  the  patient  setting  was  agreed  during  CHMP  scientific  advice.  The median PFS according to RECIST did not differ between treatment arms (3.7 vs. 1.9 months for masitinib vs. sunitinib, hazard ratio = 1.07; 95% C.I.: 0.54 ; 2.13; log-rank p-value = 0.833).

The fact that the majority of patients had progressed on a dose of imatinib of 400 mg prior to inclusion in the study is not fully in accordance with current clinical guidance, and the patient population may therefore not be representative of future patients in terms of prior exposure to imatinib. The slight imbalance in the number of dose-escalated patients between the masitinib and sunitinib groups is not considered important for the interpretation of the efficacy results.

The efficacy claim is mainly based on an exploratory analysis of the secondary endpoint overall survival  (OS)  of  trial  AB07001.  In  this  analysis  (database  cut-off  January  2012),  the  median overall  OS  for  masitinib  arm  was  estimated  to  be  at  least  21.2  months  (95%  C.I.:  21.2;  not estimable) as compared with 15.2 months in the sunitinib group (hazard ratio = 0.27; 95% C.I.: 0.09; 0.85; log-rank p-value=0.016). In an updated analysis (database cut-off December 2012), the median OS was 29.8 vs 17.4 months for masitinib versus sunitinib, respectively (hazard ratio = 0.40, 95% CI = [0.16; 0.96]; p-value = 0.033).

Firm evidence in support of efficacy claims generally requires that the results of the confirmatory trials  demonstrate that the investigational product under test has clinical benefits. Exploratory trials  generally  cannot  be  the  basis  of  the  formal  proof  of  efficacy.  In  addition,  where  the evidence  of  efficacy  is  based  on  a  single  pivotal  study,  the  study  has  to  be  exceptionally compelling and special attention has to be paid, among other aspects, to data quality, the degree of  statistical  significance  and  internal  consistency  with  all  important  endpoints  showing  similar findings.  Concerning  masitinib  in  the  claimed  indication,  evidence  from  confirmatory  trials  is lacking.  Despite  the  OS  differences  observed  in  the  exploratory  trial,  due  to  the  exploratory nature  of  the  trial  and  analyses  presented,  the  choice  of  hypothesis  may  be  data  dependent. Consequently,  the  OS  results  reported  in  the  exploratory  study  should  be  viewed  only  as hypothesis generating and would need to be confirmed in a phase III study. Furthermore, the degree of statistical significance of the exploratory OS analyses presented cannot be considered

<div style=\"page-break-after: always\"></div>

as  statistically  compelling  in  the  context  of  a  single  pivotal  trial  and  convincing  supportive evidence from other clinically relevant endpoints is lacking.

Further data have been submitted but the EPAR AR has not been updated (data not shown).

## 2.5.4. Conclusions on the clinical efficacy

The evidence provided is insufficient to establish the efficacy of masitinib. The efficacy of masitinib in GIST has not been demonstrated based on the data presented.

## 2.6. Clinical safety

## Patient exposure

The safety population included 1122 patients/healthy volunteers from 35 studies. These include 4 studies in GIST patients with masitinib used as monotherapy. In the additional studies masitinib has  been  given  as  single  agent  in  non-oncology  indications  in  much  lower  doses  than  the proposed dose or in oncology indications in combination with chemotherapy, in lower doses as well.

Overall,  423  patients  were  exposed  for  at  least  3  months  to  masitinib,  253  patients  were exposed for at least 6 months, 140 patients were exposed for at least 1 year, 77 patients for at least 2 years, and 42 patients for at least 3 years. A total of 519 patients have been treated with masitinib  as  single  agent;  however  407  of  these  patients  were  treated  for  non-oncology indications.

In the assessment the focus has therefore mainly been on the safety profile of masitinib used as monotherapy in GIST patients, thus including 112 patients.

In  contrast  to  the  Efficacy  Part  that  had  two  supportive  studies  (AB03002  and  AB04016),  the Applicant has besides these two studies also included the ongoing phase III study AB04030 in 1st GIST as supportive study in the Safety part. As this study is ongoing no Clinical Study Report (CSR) is available yet.

The cut-off date for the safety analysis of the pivotal trial AB7001 was 31 January 2012. At the time  the  pivotal  study  only  included  44  patients,  (23  were  treated  with  masitinib,  21  with sunitinib). The supportive GIST studies included 19, 30 and 40 patients, respectively.

In the pivotal study patients received a masitinib dose of 12 mg/kg/day. The supportive study AB03002 was a dose escalating trial investigating masitinib doses of 0.7 to 17.2 mg/kg/day. The dose  of  15  mg/kg/day  was  considered  dose  limiting  due  to  gastrointestinal  toxicities.  In  this study ten patients were treated with masitinib doses of 10.8 to 13.0 mg/kg/day and two patients were treated with doses of 6.8 and 8.5 mg/kg/day, respectively. The Applicant has pooled these patients  in  a  so  called  'selected  GIST  cohort'  as  they  all  received  doses  'approximating'  the proposed 12 mg/kg/day dose. In the supportive studies AB04016 and AB04030 patients were all treated with a 7.5 mg/kg/day dose.

<div style=\"page-break-after: always\"></div>

The median exposure was 4.7 months in the pivotal study and ranged from 1.8-31.5 months in the supportive studies. The longest exposure occurred in study AB04016 (median exposure 31.5 months) which resulted in an increased number of reported adverse events.

Long-term  data  (at  least  12  months)  were  only  available  for  37  patients  treated  for  GIST  of whom only a few received the proposed dose of 12 mg/kg/day. The majority received less.

## Adverse events

Adverse  events  (AE)  reported  in  at  least  5%  of  patients  according  to  treatment  arm  are displayed  in  Table  13.  The  reporting  of  common  AEs  was  overall  very  similar  in  other  GIST studies.

Table 13 - Adverse events reported in at least 5% of patients from study AB07001, according to treatment arm

| System Organ Class/Preferred Term               | MASITINIB (N=23)   | SUNITINIB (N=21)   |
|-------------------------------------------------|--------------------|--------------------|
| At least one AE                                 | 22 (95.7%)         | 21 (100%)          |
| Blood And Lymphatic System Disorders            | 13 (56.5%)         | 14 (66.7%)         |
| Anaemia                                         | 10 (43.5%)         | 6 (28.6%)          |
| Leukopenia                                      | 2 (8.7%)           | 4 (19.0%)          |
| Lymphopenia                                     | 3 (13.0%)          | 3 (14.3%)          |
| Neutropenia                                     | 2 (8.7%)           | 5 (23.8%)          |
| Thrombocytopenia                                | -                  | 6 (28.6%)          |
| Cardiac Disorders                               | 2 (8.7%)           | 1 (4.8%)           |
| Tachycardia                                     | 2 (8.7%)           |                    |
| Eye Disorders                                   | 9 (39.1%)          | 5 (23.8%)          |
| Eyelid Oedema                                   | 6 (26.1%)          | 2 (9.5%)           |
| Gastrointestinal Disorders                      | 19 (82.6%)         | 16 (76.2%)         |
| Abdominal Pain                                  | 1 (4.3%)           | 5 (23.8%)          |
| Abdominal Pain Upper                            | 3 (13.0%)          | 2 (9.5%)           |
| Cheilitis                                       | 2 (8.7%)           | 2 (9.5%)           |
| Diarrhoea                                       | 11 (47.8%)         | 11 (52.4%)         |
| Dyspepsia                                       | 1 (4.3%)           | 2 (9.5%)           |
| Gastroesophageal Reflux Disease                 | 3 (13.0%)          | 3 (14.3%)          |
| Nausea                                          | 14 (60.9%)         | 5 (23.8%)          |
| Stomatitis                                      | 2 (8.7%)           | 2 (9.5%)           |
| Vomiting                                        | 9 (39.1%)          | 2 (9.5%)           |
| General Disorders And Administration Conditions | Site 16 (69.6%)    | 18 (85.7%)         |
| Asthenia                                        | 8 (34.8%)          | 13 (61.9%)         |
| Fatigue                                         | 3 (13.0%)          | 3 (14.3%)          |
| Mucosal Inflammation                            | 1 (4.3%)           | 6 (28.6%)          |
| Oedema                                          | 3 (13.0%)          | -                  |
| Oedema Peripheral                               | 6 (26.1%)          | 4 (19.0%)          |
| Pyrexia Systemic Inflammatory Response          | -                  | 2 (9.5%)           |
| Syndrome                                        | -                  | 1 (4.8%)           |

<div style=\"page-break-after: always\"></div>

| System Organ Class/Preferred Term                         | MASITINIB (N=23)                                          | SUNITINIB (N=21)   |
|-----------------------------------------------------------|-----------------------------------------------------------|--------------------|
| Hepatobiliary Disorders                                   | -                                                         | 2 (9.5%)           |
| Hepatic Pain                                              | -                                                         | 1 (4.8%)           |
| Jaundice                                                  | -                                                         | 1 (4.8%)           |
| Infections And Infestations                               | 6 (26.1%)                                                 | 3 (14.3%)          |
| Bronchitis                                                | 2 (8.7%)                                                  | -                  |
| Urinary Tract Infection                                   | 1 (4.3%)                                                  | 2 (9.5%)           |
| Investigations                                            | 6 (26.1%)                                                 | 4 (19.0%)          |
| Blood Bilirubin Increased                                 | 2 (8.7%)                                                  | -                  |
| Weight Decreased                                          | 2 (8.7%)                                                  | 3 (14.3%)          |
| Metabolism And Nutrition Disorders                        | 7 (30.4%)                                                 | 5 (23.8%)          |
| Anorexia                                                  | 5 (21.7%)                                                 | 4 (19.0%)          |
| Musculoskeletal And Connective Tissue Disorders 4 (17.4%) | Musculoskeletal And Connective Tissue Disorders 4 (17.4%) | 8 (38.1%)          |
| Back Pain                                                 | 1 (4.3%)                                                  | 2 (9.5%)           |
| Muscle Spasms                                             | 2 (8.7%)                                                  | -                  |
| Myalgia                                                   | -                                                         | 2 (9.5%)           |
| Pain In Extremity                                         | 2 (8.7%)                                                  | 2 (9.5%)           |
| Nervous System Disorders                                  | 3 (13.0%)                                                 | 13 (61.9%)         |
| Dysgeusia                                                 | 1 (4.3%)                                                  | 6 (28.6%)          |
| Headache                                                  | 1 (4.3%)                                                  | 4 (19.0%)          |
| Psychiatric Disorders                                     | 3 (13.0%)                                                 | 3 (14.3%)          |
| Moaning                                                   | 2 (8.7%)                                                  | -                  |
| Renal And Urinary Disorders                               | 1 (4.3%)                                                  | 3 (14.3%)          |
| Respiratory And Thoracic And Mediastinal Disorders        | 5 (21.7%)                                                 | 3 (14.3%)          |
| Dyspnoea                                                  | 3 (13.0%)                                                 | 2 (9.5%)           |
| Skin And Subcutaneous Tissue Disorders                    | 14 (60.9%)                                                | 14 (66.7%)         |
| Dry Skin                                                  | 3 (13.0%)                                                 | 2 (9.5%)           |
| Erythema                                                  | 2 (8.7%)                                                  | 2 (9.5%)           |
| Palmar Plantar Erythrodysesthesia Syndrome                | 1 (4.3%)                                                  | 6 (28.6%)          |
| Rash                                                      | 7 (30.4%)                                                 | 2 (9.5%)           |
| Vascular Disorders                                        | 1 (4.3%)                                                  | 8 (38.1%)          |
| Hypertension                                              | -                                                         | 6 (28.6%)          |
| Phlebitis                                                 | -                                                         | 2 (9.5%)           |

<div style=\"page-break-after: always\"></div>

Table 14 presents all severe adverse events (i.e. adverse events of grade ≥3) reported in study AB07001.

Table 14 - Study AB07001 - Severe adverse events

| Number (%) of patients                               | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   |
|------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| with at least one                                    | All*                          | Grade 3                       | Grade 4                       | Grade 5                       | All*                          | Grade 3                       | Grade 4                       | Grade 5                       |
| At least one severe AE                               | 6 (26.1%)                     | 6 (26.1%)                     | 1 (4.3%)                      | -                             | 16 (76.2%)                    | 16 (76.2%)                    | -                             | 3 (14.3%)                     |
| Blood And Lymphatic System Disorders                 | 3 (13.0%)                     | 2 (8.7%)                      | 1 (4.3%)                      | -                             | 5 (23.8%)                     | 5 (23.8%)                     | -                             | -                             |
| Anaemia                                              | 3 (13.0%)                     | 2 (8.7%)                      | 1 (4.3%)                      | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Lymphopenia                                          | -                             | -                             | -                             | -                             | 2 (9.5%)                      | 2 (9.5%)                      | -                             | -                             |
| Thrombocytopenia                                     | -                             | -                             | -                             | -                             | 2 (9.5%)                      | 2 (9.5%)                      | -                             | -                             |
| Thrombotic Microangiopathy                           | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Cardiac Disorders                                    | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Congestive Cardiomyopathy                            | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Ear And Labyrinth Disorders                          | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Vertigo                                              | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Gastrointestinal Disorders                           | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | 2 (9.5%)                      | 2 (9.5%)                      | -                             | -                             |
| Abdominal Pain                                       | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | 2 (9.5%)                      | 2 (9.5%)                      | -                             | -                             |
| General Disorders And Administration Site Conditions | 3 (13.0%)                     | 3 (13.0%)                     | -                             | -                             | 6 (28.6%)                     | 6 (28.6%)                     | -                             | 1 (4.8%)                      |
| Asthenia                                             | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | 4 (19.0%)                     | 4 (19.0%)                     | -                             | -                             |
| General Physical Health Deterioration                | -                             | -                             | -                             | -                             | 1 (4.8%)                      | -                             | -                             | 1 (4.8%)                      |
| Fatigue                                              | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Oedema Peripheral                                    | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Mucosal Inflammation                                 | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Infections Infestations                              | And -                         | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Urinary Tract Infection                              | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Lung Infection                                       | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Injury, Poisoning Procedural Complications           | And 1 (4.3%)                  | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Wrist Fracture                                       | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Investigations                                       | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Blood Bilirubin Increased                            | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Metabolism And Nutrition Disorders                   | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Cachexia                                             | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Nervous System Disorders                             | -                             | -                             | -                             | -                             | 3 (14.3%)                     | 2 (9.5%)                      | -                             | 1 (4.8%)                      |
| Syncope                                              | -                             | -                             | -                             | -                             | 1 (4.8%)                      | -                             | -                             | 1 (4.8%)                      |
|                                                      | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1                             | -                             |                               |
| Dysgeusia                                            |                               |                               |                               |                               |                               | (4.8%)                        |                               | -                             |
| Headache                                             | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Psychiatric Disorders                                | - -                           | -                             | - -                           | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Disorientation                                       |                               | -                             |                               | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |

<div style=\"page-break-after: always\"></div>

| Number (%) of patients with at least one        | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Masitinib 12 mg/kg/d (N=23)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   | Sunitinib 50 mg/kg/d (N=21)   |
|-------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Number (%) of patients with at least one        | All*                          | Grade 3                       | Grade 4                       | Grade 5                       | All*                          | Grade 3                       | Grade 4                       | Grade 5                       |
| Respiratory, Thoracic And Mediastinal Disorders | 2 (8.7%)                      | 2 (8.7%)                      | -                             | -                             | 2 (9.5%)                      | 1 (4.8%)                      | -                             | 1 (4.8%)                      |
| Dyspnoea                                        | 2 (8.7%)                      | 2 (8.7%)                      | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Respiratory Distress                            | -                             | -                             | -                             | -                             | 1 (4.8%)                      | -                             | -                             | 1 (4.8%)                      |
| Skin And Subcutaneous Tissue Disorders          | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Pruritus                                        | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Vascular Disorders                              | -                             | -                             | -                             | -                             | 4 (19.0%)                     | 4 (19.0%)                     | -                             | -                             |
| Hypertension                                    | -                             | -                             | -                             | -                             | 3 (14.3%)                     | 3 (14.3%)                     | -                             | -                             |
| Phlebitis                                       | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |
| Rash events - All #                             | 1 (4.3%)                      | 1 (4.3%)                      | -                             | -                             | -                             | -                             | -                             | -                             |
| Oedema events - All ##                          | -                             | -                             | -                             | -                             | 1 (4.8%)                      | 1 (4.8%)                      | -                             | -                             |

## * All = from grade 3 to grade 5

#'Rash  events  -  All'  includes  the  following  MedDRA  preferred  terms:  excoriation;  acne;  giant  urticaria; blister;  dermatitis;  dermatitis  acneiform;  dermatitis  allergic;  dermatitis  psoriasiform;  dry  skin;  eczema; erythema;  erythema  diffuse;  erythema  multiforme;  erythema  nodosum;  generalized  erythema;  guttate psoriasis;  dry  hair;  idiopathic  urticaria;  mucocutanous  rash;  palmar  erythema;  hand  and  foot  syndrome; pruritus;  pruritus  allergic;  rash;  rash  erythematous;  rash  generalised;  rash  macula-papular;  rash  pruritic; skin bleeding; skin burning sensation; skin desquamation; skin exfoliation; skin fissure; skin inflammation; skin irritation;  skin  lesion;  skin  reaction;  skin  toxicity;  toxic  skin  eruption;  urticaria;  urticaria  generalised; urticaria localized; urticaria papular; urticaria pigmentosa.

## 'Oedema  events  -  All'  includes  the  following  MedDRA  preferred  terms:  eye  oedema,  eyelid  oedema, orbital  oedema,  periorbital  oedema,  gingival  oedema,  oedema  mouth,  tongue  oedema,  face  oedema, generalised  oedema,  localized  oedema,  oedema,  oedema  peripheral,  allergic  oedema,  breast  oedema, oedema genital, scrotal oedema, testicular swelling, lymphedema.

## Serious adverse event/deaths/other significant events Deaths

All deaths but those clearly related to the disease per protocol definitions and except deaths that were not related to the investigational product, are discussed in this section.

None  of  the  masitinib-treated  patients  died  during  study  AB07001.  Among  sunitinib-treated patients,  three  deaths  were  reported,  none  of  which  were  considered  related  to  the  study treatment.

None of the deaths occurring in study AB04016 were related to masitinib treatment.

One death suspected to be related to masitinib was reported in study AB04030: acute pulmonary oedema.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events (SAEs)

Non-fatal serious adverse events reported in study AB07001 are displayed in the table below.

Table 15 - Study AB07001 - Description of non-fatal serious adverse events

| Number (%) of patients with at least one                                | Masitinib 12 (N=23)   | mg/kg/d Sunitinib (N=21)   | 50                         | mg/   | d   |
|-------------------------------------------------------------------------|-----------------------|----------------------------|----------------------------|-------|-----|
| At least one non-fatal SAE At least one suspected non-fatal SAE         | 3 (13.0%) -           |                            | 7 (33.3%) 4 (19.0%)        |       |     |
| Blood And Lymphatic System Disorders Anaemia Thrombotic Microangiopathy | 1 (4.3%) 1 (4.3%) -   |                            | 2 (9.5%) 1 (4.8%) 1 (4.8%) |       |     |
| Cardiac Disorders Congestive Cardiomyopathy                             | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |
| Gastrointestinal Disorders Abdominal Pain Vomiting                      | 1 (4.3%) 1 (4.3%) -   |                            | 2 (9.5%) 1 (4.8%) 1 (4.8%) |       |     |
| General Disorders And Administration Site Conditions Asthenia           | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |
| Infections And Infestations Lung Infection Urinary Tract Infection      | - - -                 |                            | 1 (4.8%) 1 (4.8%) 1 (4.8%) |       |     |
| Investigations Blood Creatinine Increased                               | 1 (4.3%) 1 (4.3%)     |                            |                            |       |     |
| Metabolism And Nutrition Disorders Cachexia                             | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |
| Psychiatric Disorders Disorientation                                    | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |
| Renal And Urinary Disorders Renal Failure                               | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |
| Vascular Disorders Phlebitis                                            | - -                   |                            | 1 (4.8%) 1 (4.8%)          |       |     |

None of SAEs in the masitinib arm were considered treatment-related by the investigators. In the sunitinib  arm  none  of  the  observed  SAEs  was  reported  more  than  once.  Some  patients experienced more than one SAE. The reported SAEs were considered treatment-related in four patients.

A  limited  number  of  suspected  treatment-related  SAEs  were  reported  in  the  small  doseescalating study AB03002. More SAEs were reported in the ongoing phase III study AB04030 in 1 st  line that has only enrolled 40 patients in the masitinib arm. So far 8 of these patients have reported  SAEs.  The  most  common  were  anaemia  (3  patients),  diarrhoea  (2  patients)  and dyspnoea (2 patients). Only 2 reports of SAEs (anaemia, psoriasis) derived from study AB04016.

<div style=\"page-break-after: always\"></div>

## Events of Special Interest

During  the  assessment,  the  applicant  was  requested  to  provide  a  thorough  discussion  of masitinib  Adverse  Events  of  Special  Interest  (AESI)  in  relation  to  other  TKIs,  which  is summarised below:

- Adverse events more frequently observed with masitinib than with most registered TKIs, but not necessarily sunitinib were: nausea and vomiting, skin rash and oedema.
- Adverse events observed with masitinib at a similar frequency than with most registered TKIs were: diarrhoea, musculoskeletal complaints and renal toxicity
- Adverse events less frequently observed with masitinib than with most registered TKIs were: fatigue, hepatotoxic events, stomatitis, haemorrhage, anaemia, neutropenia, severe skin toxicity, thrombocytopenia and pancytopenia, hypothyroidism and cardiotoxicity.

Signals of potential concern have been identified in relation to cardiotoxicity, QT prolongation and skin toxicities.

## Laboratory findings

In general, it has been difficult to get an overview of laboratory values. Patients with a normal biochemistry value at baseline in the pivotal study receiving masitinib did not shift to a grade 3 or 4 value except for one patient (of the 21 patients) with normal albumin at baseline decreasing to  a  grade  3  albumin  level  and  two  patients  (out  of  15  patients)  with  normal  phosphorus  at baseline decreasing to grade 3 level. However, shifts from normal at baseline to grade 1 and 2 were common in the pivotal study concerning phosphorus decreased, bilirubin increased, alkaline phosphatase increased, gamma-GT increased, AST increased, ALT increased, glucose increased and  calcium  increased.  Overall,  the  same  pattern  was  observed  for  sunitinib  except  that  the alkaline  phosphatase  seems  to  increase  in  three  times  more  patients  receiving  masitinib compared to sunitinib.

In  patients  receiving  sunitinib  a  higher  proportion  of  patients  had  albumin  decreased  and potassium increased in patients having normal albumin or potassium, respectively, at baseline.

The  shifts  in  biochemistry  in  the  pivotal  study  are  roughly  in  accordance  with  the  shifts  in biochemistry in the supportive studies taking the small number of patients into account.

Concerning haematological  changes in the pivotal study decreased values of especially haemoglobin  but  also  other  haematological  values  were  observed  in  the  masitinib  treated patients. However, it was mainly to grade 1 and to a lesser extend grade 2. Only two patients were  observed  with  grade  3  decreases  (one  haemoglobin  and  one  lymphocytes).  No  grade  4 decreases were observed.

## Safety in special populations

No data have been submitted in patients with impaired renal or hepatic function.

In the pivotal study no major differences were observed concerning the safety profile according to  age  (&lt;=65  vs.  &gt;65  years  old).  However,  no  conclusion  can  be  drawn  in  view  of  the  small number of subjects.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

In the pivotal study only one patient in the masitinib arm discontinued treatment due to an AE (dyspnoea) compared with three patients in  the  sunitinib  arm.  Only  two  of  the  causal  events were considered treatment-related (anaemia, asthenia and disorientation.)

Limited  information  comes  from  the  supportive  GIST  studies:  No  patients  discontinued  study drug due to AEs in study AB04016. Three patients discontinued treatment in the dose escalating study AB03002, two of these patients belonged to the 'selected GIST cohort' (events leading to discontinuation: nausea, salivary hypersecretion, vomiting, anorexia). Four patients discontinued masitinib due to AEs in the ongoing phase III trial ABO4030 (events leading to discontinuation: diarrhoea, liver transaminase elevations, dyspnoea and hypertension).

In  the  pivotal  study  6  patients  (26.1%) in  the  masitinib  arm  experienced  AEs  leading  to  dose reductions compared to 9 patients (42.9%) in the sunitinib arm. In the masitinib arm only three of  these  patients  had  events  that  were  considered  treatment-related  (elevated  transaminase level, oedema, pruritus).

In the supportive GIST studies few patients required dose-reductions due to treatment-related events. Two patients in study AB04030 required dose reductions due to development of rash. Of note,  there  were  only  two  reports  of  dose  reductions  due  to  diarrhoea  or  gastrointestinal disturbances  in  the  masitinib  arm  although  these  events  were  commonly  associated  with masitinib.

## Post marketing experience

Not applicable.

## 2.6.1. Discussion on clinical safety

The safety population included 1122 patients/healthy volunteers from 35 studies. However, the total GIST safety population (n=) included patients from the pivotal phase II study (AB07001) and  from  3  supportive  studies  (dose  escalating  phase  I  study  AB03002,  single-arm  phase  II study AB04016 in 1 st line and the ongoing phase III study AB04030 in 1 st line). Only 23 patients from  the  pivotal  study  received  masitinib  as  2 nd line  treatment  at  the  proposed  dose  of  12 mg/kg/day. In addition, ten patients in the dose-escalating study received masitinib doses in the range of 10.8 to 13.0 mg/kg/day. In the additional studies masitinib has been given as single agent  in  non-oncology  indications  in  much  lower  doses  than  the  proposed  or  in  oncology indications in combination with chemotherapy, in lower doses as well.

Almost all patients in the pivotal study AB07001 reported at least one AE (22/23 or 95.7% in the masitinib arm and 21/21 or100% in the sunitinib arm).

The most common AEs associated with masitinib (&gt; 25%) were nausea (14 patients: 60.9%), diarrhoea (11 patients: 47.8%), anaemia (10 patients: 43.5%), vomiting (9 patients: 39.1%), asthenia (8 patients: 34.8%), rash (30.4%), peripheral/eyelid oedema (6 patients: 26.1%). The reporting of common AEs was similar in other GIST studies.

These  events  are  all  representing  well  known  safety  characteristics  of  TKIs.  However,  subtle differences exist due to differences in kinase selectivity which result in slightly different safety profiles among these agents. For instance, it seems that nausea, vomiting, rash and peripheral

<div style=\"page-break-after: always\"></div>

oedema are more commonly associated with masitinib whereas patients treated with sunitinib have a higher risk of developing asthenia, thrombocytopenia, PPES and hypertension.

After  the  update  of  the  safety  database  following  the  GCP  inspection,  twelve  (47.8%)  of  the masitinib-treated patients reported at least one severe adverse event. The most common severe events  in  the  masitinib  arm  were  Anaemia  (3  patients)  and  Dyspnoea  (2  patients).  Only  one event  of  Anaemia  was  of  grade  4,  the  rest  of  the  severe  events  were  grade  3.  The  safety database update revealed that 11 (47.8%) patients in the masitinib group experienced a nonhaematological Grade 3 or 4 AE.

More  patients  reported  severe  events  in  study  AB04016  (phase  II,  1 st line),  mainly  rash, gastrointestinal  disorders  and  anaemia/neutropenia,  which  can  be  explained  by  the  longer exposure. Furthermore, more severe events were also reported in the ongoing phase III study AB04030 (1 st   line),  particularly  liver  transaminase  elevations  and  blood  and  lymphatic  system disorders despite a lower dose being used.

At least one nonfatal SAE was reported in 7 patients (33.3%) in the sunitinib arm compared with 3 patients (13.0%) in the masitinib arm. The 3 reports of SAEs in the masitinib arm include one case of anaemia, one case of increased blood creatinine and one case of abdominal pain. None of these events were considered treatment-related by the investigators. The reported frequencies should be interpreted with caution due to the limited total number of patients enrolled in the pivotal study.

A  limited  number  of  suspected  treatment-related  SAEs  were  reported  in  the  small  doseescalating study AB03002. More SAEs were reported in the ongoing phase III study AB04030 in 1 st  line that has only enrolled 40 patients in the masitinib arm. So far 8 of these patients have reported  SAEs.  The  most  common  were  anaemia  (3  patients),  diarrhoea  (2  patients)  and dyspnoea (2 patients). Only 2 reports of SAEs (anaemia, psoriasis) derived from study AB04016. However, supportive  data  is  also  available  from  a  limited  number  of  patients,  the  majority  of which were treated at a lower dose and therefore does not allow drawing conclusion.

In the pivotal trial there were no reported deaths in the masitinib arm. There were three deaths in the sunitinib arm but none were considered treatment- related. In the supportive studies only one fatality was considered treatment-related. It concerned a 77-year old patient who died of acute  pulmonary  oedema  5  months  after  starting  masitinib  treatment.  An  update  of  reported SAEs and deaths in ongoing studies in GIST was requested, and no new safety signal has been identified.

Discontinuations of treatment due to an AE was only observed in one patient in the masitinib arm in  the  pivotal  study  (dyspnoea)  compared  with  3  patients  in  the  sunitinib  arm.  However, 6 patients (26.1%) experienced AEs leading to dose reductions in the masitinib arm compared to 9 patients (42.9%) in the sunitinib arm.

Haematological  shifts  from  normal  at  baseline  to  worst  grade  under  treatment  in  masitinib treated patients in the pivotal study were observed. Decreased values of especially haemoglobin, lymphocytes and leucocytes were observed, however, it was mainly to grade 1 and grade 2. No severe neutropenia was reported in any of the GIST studies; however, severe neutropenia was reported in other indications including a severe serious adverse event of neutropenia in a healthy

<div style=\"page-break-after: always\"></div>

volunteer.  Shifts  in  biochemistry in  the  pivotal  study  were  mainly  grade  1-2  and  concerned especially hepatic parameters.

Cardiotoxicity  is  considered  a  potential  safety  concern  in  view  of  findings  in  preclinical  studies (impact on hERG, fibrosis and myocardial degeneration) after masitinib treatment and cardiac AEs, SAEs, one sudden death and one case 'death' included in the safety database.

Furthermore,  a  very  small  study  in  healthy  volunteers  showed  prolonged  QT  after  masitinib doses of 200 and 800 mg (see clinical pharmacology section). Newer tyrosine kinase inhibitors used in the treatment of various cancers have been noted to cause significant QT prolongation. Sunitinib, nilotinib, and dasatinib have been associated with varied amounts of QT prolongation at 10 msec, 5 to 15 msec, and 3.3 msec, respectively. In the ongoing blinded phase 3 study, AB07012, (masitinib in combination with chemotherapy) one sudden death had been observed. Arrhythmia NOS have been described two times (in the same patient) in study AB 06006 as nonfatal  SAE.  Two  AE  cases  of  tachycardia  (8.7%)  have  been  observed  in  the  pivotal  study; however, the type of tachycardia has not been described. In addition, in 'other GIST studies' 3 cases (15.8%) of tachycardia were observed in AB03002. Syncope's have not been observed in the pivotal study but were observed in more of the other masitinib studies. Furthermore, in an uncontrolled  study  with  masitinib  in  combination  with  chemotherapy,  one  patient  had  QTprolongation.  No  cases  of  Torsade  de  Pointes  have  been  observed,  however,  such  cases  are seldom captured in clinical trials. As discussed in the clinical pharmacology section, an effect of masitinib on QTc cannot be ruled out and a thorough QT/QTc study according to the guideline (CHMP/ICH/2/04 E14, The clinical evaluation of QT/QTs interval prolongation and pro-arrhythmic potential for non-anti-arrhythmic drugs) would be required to address whether masitinib has the potential to induce QTc interval prolongation.

Skin toxicity was also of concern in view of 18 SAEs observed in the entire database including several cases of toxicodermia and one case of Baboon syndrome. The cases generally occurred within some weeks after treatment start, were mainly grade 3 and resolved with sequelae. AEs of skin and subcutaneous tissue disorders were observed in 56.5% in the pivotal study and this was overall  in  line  with  the  observations  in  the  supportive  studies.  Additionally,  a  case  of  StevenJohnson syndrome was diagnosed clinically by a dermatologist. No biopsy was taken from the patient to confirm the diagnosis histopathologically. The effect of masitinib on the kidney function is considered uncertain. The elimination route of masitinib has been shown to be almost entirely extra-renal. However, pre-clinical studies showed prevalence of blood and protein in the urine in dogs  and  rats  and  histopathological  findings  of  tubular  cell  degeneration/necrosis  in  rats. Proteinuria  was  observed  overall  in  7.3%  of  the  patients  in  the  supportive  GIST  studies, however, no cases were observed in the pivotal study. In addition several different AEs, non-fatal SAEs and deaths due to the kidney function have been described in the entire safety database. No formal renal study was included with this submission. Therefore, the effect on masitinib on the kidney function should be further characterised.

Similarly, the potential influence of masitinib on liver function has not been thoroughly discussed. In preclinical studies liver toxicity was observed (increase of hepatic enzyme activity, decreased plasma concentrations of protein and albumin and microscopic changes such as bile canalicular plugs and vacuolated Kupffer cells). The metabolism of masitinib is mainly hepatic. GIST patients may have hepatic metastases which can lead to hepatic impairment. No patients in the pivotal study experienced hepatobiliary disorders; however, 16.7% of the patients in the selected cohort

<div style=\"page-break-after: always\"></div>

of the supportive GIST study AB03002 (or 21% of all patients in the same study) experienced hyperbilirubinemia. Increase in transaminases, gamma GT, bilirubin and LDH were common in the  pivotal  study.  In  the  entire  safety  database  cases  of  cytolytic  hepatitis  were  observed. According  to  the  applicant  no  fatal  liver  disorder  was  considered  as  related  to  masitinib.  . Therefore,  starting  dose  adjustment  in  patients  with  mild  to  moderate  liver  impairment,  dose reductions or treatment interruptions for hepatic adverse reaction would  be  considered warranted.

Further data have been submitted but the EPAR AR has not been updated (data not shown).

## 2.6.2. Conclusions on the clinical safety

Although masitinib has been investigated in a number of indications in various doses, the safety database only included a very limited number of GIST patients (n=112), of which only very few (23 patients in the pivotal phase II trial and 10 patients [dose range of 10.8 to 13.0 mg/kg/day] in the dose escalating study) have actually been treated with the proposed dose of 12 mg/kg/day. Consequently, the safety database is considered insufficient to allow an adequate assessment of the risks associated with masitinib in the proposed indication and posology.

Common AEs associated with masitinib are characteristic of the well-known safety profile of other TKIs, however, signals of potential concern have been identified in relation to cardiotoxicity, QTc prolongation and renal toxicity that would require further investigations.

Therefore, the safety of masitinib is not considered to have been adequately studied.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to conclude on pharmacovigilance system at this time.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

## PRAC Advice

Based on the PRAC review of the Risk Management Plan version 3.0 the PRAC considered by consensus that the risk management system for masitinib (Masican) for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after progression with imatinib treatment could be acceptable provided minor revisions were made to the RMP

This advice is based on the following content of the Risk Management Plan:

<div style=\"page-break-after: always\"></div>

## · Safety concerns

The applicant identified the following safety concerns in the RMP:

Table 16 - Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Severe neutropenia Severe skin toxicity Oedema and fluid retention Liver toxicity Proteinuria Creatinine increased Interstitial lung disease                                                                                                                                                                                                                                                    |
| Important potential risks    | Disseminated intravascular coagulation Cardiac toxicity Hypertension Hypotension Hypothyroidism Reproductive toxicity Carcinogenicity Off label use                                                                                                                                                                                                                                             |
| Missing information          | Efficacy and safety in children < 18 years Use in pregnant or lactating women Use in patients with grade ≥ 3 liver enzymes increased Use in patients with grade ≥ 2 blood creatinine increased Potential of drug interaction with masitinib Effect of masitinib on the fertility Long-term efficacy and safety of masitinib at 12 mg/kg/day Use in patients with ECOG score > 2 Embryo toxicity |

The PRAC considers that the updated summary of safety concerns submitted by the Applicant is acceptable though 'creatinine increased' should be corrected to 'creatinine increase' or 'creatinine increases'.

## · Pharmacovigilance plans

Table 17 - Ongoing and planned studies in the PhV development plan

| Activity/Study title (category 1-3)*   | Objectives                                    | Safety concerns addressed   | Status   | Date for submission of interim or final reports   |
|----------------------------------------|-----------------------------------------------|-----------------------------|----------|---------------------------------------------------|
| QT/QTc study                           | To assess the effects of single oral doses of | Cardiac toxicity            | Proposed | Not finalised                                     |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (category 1-3)*                                                                      | Objectives                                                                                           | Safety concerns addressed                                 | Status   | Date for submission of interim or final reports   |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|----------|---------------------------------------------------|
|                                                                                                           | masitinib on QTc Interval compared to placebo using moxifloxacin as positive control.                |                                                           |          |                                                   |
| Specific drug drug interactions studies testing the pharmacokinetics of masitinib with CYP3A4 inhibitor   | To evaluate pharmacokinetic interaction between itraconazole, an inhibitor of CYP3A4, and masitinib  | Drug drug interactions masitinib with inhibitor of CYP3A4 | Planned  | Not finalised                                     |
| Specific drug drug interactions studies testing the pharmacokinetics of masitinib with CYP3A4 inducer     | To evaluate pharmacokinetic interaction between dexa- methasone, an inducer of CYP3A4, and masitinib | Drug drug interactions masitinib with inducer of CYP3A4   | Ongoing  | End of 2013                                       |
| Systematic hormonal work up in non-menopausal female patients enrolled in the nononcology clinical trials | Explore a potential relationship between masitinib and hormonal unbalance in female patients         | Reproductive toxicity                                     | Ongoing  | Unknown                                           |

*Category 1 are imposed activities considered key to the benefit risk of the product.

Category 2 are specific obligations

Category 3 are required additional PhV activity (to address specific safety concerns or to measure effectiveness of risk minimisation measures)

The PRAC noted various inconsistencies and ambiguities in the PhV plan for Masican.

## · Risk minimisation measures

## Table 18 - Summary table of Risk Minimisation Measures

| Safety concern       | Routine risk minimisation measures                                                                                                                        | Additional risk minimisation measures     |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Severe neutropenia   | Posology adaptation, labeling of neutropenia                                                                                                              | Complete blood counts performed regularly |
| Severe skin toxicity | Labeling of rash, pruritus, dry skin, erythema, alopecia, palmar plantar erythrodysthesia, onychoclasis, nail toxicity, pigmentation disorders, psoriasis | None                                      |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Routine risk minimisation measures                                                                                                      | Additional risk minimisation measures   |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Oedema and fluid retention | Labeling of eyelid oedema, oedema peripheral, face oedema and oedema.                                                                   | None                                    |
| Liver toxicity             | Posology adaptation, labeling of transaminases increased, gamma GT increased, bilirubine increase, LDH increase and hyperbilitubinaemia | Liver tests performed regularly         |
| Proteinuria                | Posology adaptation, labeling of proteinuria                                                                                            | Renal tests performed regularly         |
| Creatinine increased       | Posology adaptation, labeling of creatinine increased                                                                                   | Renal tests performed regularly         |
| Interstitial lung disease  | Labeling of interstitial lung disease                                                                                                   | None                                    |
| Cardiac toxicity           | Labeling of tachycardy                                                                                                                  | None                                    |
| Hypertension               | Labeling of hypertension                                                                                                                | None                                    |
| Hypotension                | None, pharmacovigilance routine activities are considered as sufficient                                                                 | None                                    |
| Hypothyroidism             | None, pharmacovigilance routine activities are considered as sufficient                                                                 | None                                    |
| Reproductive toxicity      | Contraception is mandatory during and 4 months after the treatment                                                                      | None                                    |
| Carcinogenicity            | Preclinical safety findings are mentioned in the SmPC                                                                                   | None                                    |
| Off label use              | The indication is clearly specified in the SmPC                                                                                         | None                                    |

The PRAC noted that the summary table in Part V.1 was lacking information on missing information and requires updating in this regard. Specifically, the Applicant should consider whether risk minimisation measures for embryotoxicity are warranted.

Finally, the PRAC noted that the Applicant had erroneously considered the proposed risk minimisation measures for severe neutropenia, liver toxicity, proteinuria and creatinine increased as additional risk minimisation measures and these should be properly classified in an updated RMP.

The CHMP endorsed this advice without changes.

The CHMP, having considered the data submitted in the application was of the opinion that it was not appropriate to consider risk minimisation activities at this time.

## 2.9. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet does not yet meet the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

The proposed indication is treatment of unresectable and/or metastatic malignant GIST in adults after progression with imatinib treatment.

The efficacy claim is mainly based on an exploratory analysis of the secondary endpoint overall survival  (OS)  of  trial  AB07001.  In  this  analysis  (database  cut-off  January  2012),  the  median overall  OS  for  masitinib  arm  was  estimated  to  be  at  least  21.2  months  (95%  C.I.:  21.2;  not estimable) as compared with 15.2 months in the sunitinib group (hazard ratio = 0.27; 95% C.I.: 0.09; 0.85; log-rank p-value=0.016). In an updated analysis (database cut-off December 2012), the median OS was 29.8 vs 17.4 months for masitinib versus sunitinib, respectively (hazard ratio = 0.40, 95% CI = [0.16; 0.96]; p-value = 0.033). The median PFS was 3.7 vs. 1.9 months for masitinib  vs.  sunitinib,  respectively  (hazard  ratio  =  1.07;  95%  C.I.:  0.54  ;  2.13;  log-rank  pvalue = 0.833). One (4.3%) patient in the masitinib arm and two (9.5%) patients in the sunitinib arm  achieved  a  partial  response  according  to  Response  Evaluation  Criteria  In  Solid  Tumors (RECIST).

The  beneficial  effects  of  Masican  in  the  proposed  indication  have  not  been  established  (see Uncertainty in the knowledge of the beneficial effects).

## Uncertainty in the knowledge about the beneficial effects.

The pharmacokinetics of masitinib would require further investigation, particularly with regards to proposed posology. Additional studies in special populations and a thorough QT/QTc study are also needed.

In  the  setting  of  a  marketing  authorisation  application  supported  by  a  single  pivotal  study, special attention has to be paid to data quality. A Good Clinical Practice (GCP) inspection of the sponsor site and of two clinical trial sites of pivotal trial AB07001 revealed numerous critical and major  findings  related  to  the  conduct  of  the  study  and  collection  of  efficacy  and  safety  data, including poor adherence to scheduling of visits to assess progression-free survival (PFS). The Applicant  has  responded  to  the  numerous  GCP  inspection  findings  with  corrective  measures whenever possible.

In study AB07001 the statistical hypotheses were defined to test if median PFS was sufficiently long to imply that masitinib will be chosen for further studies or if PFS was too short for masitinib to be chosen for further studies. From a statistical point of view, this study was not designed as comparative  between  masitinib  and  sunitinib,  and  any  comparison  between  groups  was exploratory.

Firm evidence in support of efficacy claims generally requires that the results of the confirmatory trials demonstrate that the investigational product under test has clinical benefits. Exploratory trials generally cannot be the basis of the formal proof of efficacy. In addition, where the evidence of efficacy is based on a single pivotal study, the study has to be exceptionally compelling and special attention has to be paid, among other aspects, to data quality, to the degree of statistical significance and internal consistency with all important endpoints showing

<div style=\"page-break-after: always\"></div>

similar findings. Concerning masitinib in the claimed indication, evidence from confirmatory trials is lacking. Despite the OS differences observed in the exploratory trial, due to the exploratory nature of the trial and analyses presented, the choice of hypothesis may be data dependent. Consequently, the OS results reported in the study should be viewed only as hypothesis generating and would need to be confirmed in a phase III study. Furthermore, the degree of statistical significance of the exploratory OS analyses presented cannot be considered as statistically compelling in the context of a single pivotal trial and convincing supportive evidence from other clinically relevant endpoints is lacking. Thus, the evidence provided is insufficient to establish the efficacy of masitinib.

From a quality perspective, the lack of sufficient information on the manufacture and controls of the drug substance as a result of unsuitable starting material means that only when adequate information  on  the  drug  substance  manufacturing  process  and  controls  is  provided  could  the grant of the market authorisation be considered.

## Risks

## Unfavourable effects

The safety database is considered insufficient to allow an adequate assessment of the risks associated with masitinib in the proposed indication and posology (see Uncertainty in the knowledge about the unfavourable effect).

The  most  common  AEs  associated  with  masitinib  (&gt;  25%)  in  the  pivotal  were  nausea (14 patients: 60.9%), diarrhoea (11 patients: 47.8%), anaemia (10 patients: 43.5%), vomiting (9  patients:  39.1%),  asthenia  (8  patients:  34.8%),  rash  (30.4%),  peripheral/eyelid  oedema (6 patients: 26.1%). These events are all representing well known safety characteristics of TKIs.

Haematological  changes  from  normal  at  baseline  to  worst  grade  under  treatment  in  masitinib treated patients in the pivotal study were observed. Decreased values of especially haemoglobin, lymphocytes and leucocytes were observed, however, it was mainly to grade 1 and grade 2. No severe neutropenia was reported in any of the GIST studies; however, severe neutropenia was reported in other indications including a severe serious adverse event of neutropenia in a healthy volunteer.

Changes in biochemistry in  the  pivotal  study  were  mainly  grade  1-2  and  concerned  especially hepatic parameters.

## Uncertainty in the knowledge about the unfavourable effects

Although masitinib has been investigated in a number of indications in various doses, the safety database  only  included  a  very  limited  number  of  GIST  patients  of  which  only  very  few  (23 patients in the pivotal phase II trial and 10 patients [dose range of 10.8 to 13.0 mg/kg/day] in the dose escalating study) have actually been treated with the proposed dose of 12 mg/kg/day.

The sample size of the pivotal (and supportive studies) in GIST is too small to allow an adequate assessment of the risks associated with masitinib. When comparing the reported severe events in the pivotal trial with the observed severe events in the supportive GIST studies, it is noted that more patients reported severe events in study AB04016 (1st line), mainly rash, gastrointestinal disorders  and  anaemia/neutropenia,  which  can  be  explained  by  the  longer  exposure.  Notably,

<div style=\"page-break-after: always\"></div>

more  severe  events  were  also  reported  in  the  ongoing  phase  III  study  ABO4030  (1st  line), particularly  liver  transaminase  elevations  and  blood  and  lymphatic  system  disorders  despite  a lower dose being used. It raises a concern that the reporting of laboratory abnormalities is more complete in the ongoing phase III trial.

Newer TKIs used in the treatment of various cancers have been noted to cause significant QT prolongation.  Limited  QTc  data  from  two  studies  in  healthy  volunteers  has  been  provided.  An increase in QT of 15-20 ms from baseline was observed in one study but not in the other study. Two  cases  of  tachycardia  (8.7%)  have  been  observed  in  the  pivotal  study.  Finaly,  preclinical studies have shown signals concerning cardiotoxicity. No studies have been conducted in patients with renal and hepatic impairment. In view of nonclinical findings and reported renal and hepatic disorders, the effect of masitinib on the kidney function and on the liver remains uncertain.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Efficacy results reported in the study should be viewed only as hypothesis generating and would need to be confirmed in a phase III study. Furthermore, the degree of statistical significance of the  exploratory  OS  analyses  presented  cannot  be  considered  as  statistically  compelling  in  the context of a single pivotal trial and convincing supportive evidence from other clinically relevant endpoints  is  lacking.  Thus,  the  evidence  provided  is  insufficient  to  establish  the  efficacy  of masitinib.  The  safety  profile  of  masitinib  does  not  cause  immediate  concerns.  However,  the number of GIST patients treated at the proposed posology is too limited to allow an adequate assessment of the risk associated with masitinib.

From a quality perspective, the lack of sufficient information on the manufacture and controls of the drug substance as a result of unsuitable starting material means that only when adequate information  on  the  drug  substance  manufacturing  process  and  controls  is  provided  could  the grant of the market authorisation be considered.

## Discussion on the benefit-risk balance

The efficacy of masitinib in GIST has not been sufficiently demonstrated. The safety database is considered insufficient to allow an adequate assessment of the risks associated with masitinib in the  proposed indication  and  posology.  Furthermore,  the  quality  of  the  product  is  insufficiently controlled with regards patient exposure to impurities.

The  overall  benefit-risk  of  Masican  (masitinib)  in  the  proposed  GIST  indication  is  considered negative.

The CHMP considered that the requirements for a conditional approval laid down in Article 4 of Commission  Regulation  (EC)  No  507/2006,  namely  the  benefit  risk  balance  of  the  medicinal product, as defined in Article 1(28a) of Directive 2001/83/EC, is positive, has not been fulfilled. In addition, the timely completion of further studies required for the confirmation of a positive benefit risk balance cannot be expected in light of the observed recruitment so far in the ongoing confirmatory study. The benefit to public health of the immediate availability on the market of masitinib  has  not  been  justified  and  does  not  outweigh  the  risk  inherent  in  the  fact  that additional data are still required.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Masican in the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after progression with imatinib treatment, the CHMP considers by consensus that the quality, safety and efficacy of the above mentioned medicinal product is not sufficiently demonstrated, and, therefore recommends the refusal of the granting of the conditional Marketing Authorisation for the above mentioned medicinal product. The CHMP considers that:

- The efficacy of masitinib in GIST has not been sufficiently demonstrated;
- The safety database is considered insufficient to allow an adequate assessment of the risks associated with masitinib in the proposed indication and posology;
- The quality of the product is insufficiently controlled with regards patient exposure to impurities and the reproducibility between biobatches and commercial batches cannot be guaranteed.

Furthermore, the CHMP, in light of the negative recommendation, is of the opinion that it is not appropriate to conclude on the new active substance status at this time.

## 5. Re-examination of the CHMP opinion of 21 November 2013

Following the CHMP conclusion that Masican was not approvable due to the lack of an established efficacy, insufficient safety database and due to the insufficiently controlled quality of the product, the applicant submitted detailed grounds for the re-examination of the grounds for refusal.

## Detailed grounds for re-examination submitted by the applicant

The applicant presented in writing and at an oral explanation.

A summary of the applicant's grounds for re-examination is presented below. Clinical Ground No. 1 (exploratory nature of the study with no planned statistical comparisons between  masitinib  and  sunitinib):  The  applicant  considered  that  the  study  was  rather  a confirmatory study in view of ICH E9 guideline on Statistical Principles for Clinical Trial (dated 05 February 1998): The statistical hypothesis done on the primary analysis of study AB07001 was pre-specified and did not change according to the PFS data obtained, these PFS data not being available at the time of the choice of the statistical hypothesis but 1 year later once the CT-scans were centrally and blindly reviewed. The statistical tests performed on this primary analysis were conclusive. Statistical tests on the secondary analysis of OS (based on p-values and hazard ratios for  death  with  their  95%  confidence  intervals)  were  pre-specified,  never  changed  during  the course of the study, and were also conclusive. Even if the sequence of secondary analyses on PFS and OS had not been pre-specified, there is still a statistically significant difference in terms

<div style=\"page-break-after: always\"></div>

of OS between masitinib and sunitinib treatment-arms when using a conservative approach such as the Bonferroni method. The observed median OS of 29 months in the masitinib treatment-arm of  study  AB07001  confirms  previous  results  obtained  from  a  phase  1  study  of  masitinib  in advanced GIST patients, i.e. a comparative median OS of 29.8 months, when also factoring in published  survival  data  of  sunitinib  in  third-line.  Finally,  the  applicant  considered  that  the guideline  on  conditional  approval  (EMEA/509951/2006)  states  that  a  confirmatory  study  is needed,  meaning  that  the  presented  phase  II  study  might  legitimately  have  an  exploratory aspect.

Clinical  Ground  No.  2 (results  of  overall  survival  not  supported  by  other  endpoints):  The applicant considered that although PFS may provide valuable insights in certain clinical trials, OS remains, however, the gold standard for assessing efficacy in oncology, in particular for GIST. The statistical validation of surrogate endpoints such as PFS requires a high correlation between the treatment effects on PFS and OS for each indication and each treatment. In reality, a wide variety  of  oncological  treatments  fail  to  show  a  correlation  between  PFS,  or  other  surrogate endpoints, and OS.

Clinical  Ground    No.  3 (the  mechanism  of  action  of  masitinib  may  explain  an  effect  on  OS without any action on PFS): The applicant considered that evidence have demonstrated that the efficacy results observed for the masitinib treatment-arm of study AB07001, i.e. OS improvement with no impact on PFS, are consistent with, and corroborated by, the mechanisms of action (MoA) of both masitinib and sunitinib. This ability was not limited to patients with GIST since it was also observed in pancreatic cancer patients, in the Tel-Jak2 mice model of leukemia and  in  dogs  with  mast  cell  tumors.  Taken  together  this  demonstrates  the  findings  of  study AB07001 are not a chance finding.

Clinical Ground  No. 4 (results  of  study  AB07001 cannot be considered as compelling in the context of a single pivotal trial): The applicant's position was as follows: The CHMP guideline, CPMP/EWP/2330/99  on  points  to  consider  on  validity  and  interpretation  of  one  pivotal  study, applies for full approval but does not fit the context of conditional approval.

Clinical Ground  No. 5 (safety database is insufficient to allow an adequate assessment of the risks associated with masitinib in the proposed indication and posology): The safety of masitinib in GIST is sufficient since it is based on 174 masitinib-treated patients suffering from GIST (cutoff  date  31  August  2013).  This  safety  population  consists  of  imatinib-resistant  GIST  patients receiving  masitinib  at  12  mg/kg/day  and  imatinib-naïve  GIST  patients  receiving  masitinib  at around 7.5 mg/kg/day, the pharmacokinetics of masitinib in these patients being not different.

In addition, the overall safety profile of masitinib at the cut-off date of 31 August 2013 is based upon  1554  masitinib-treated  patients  including  healthy  volunteers,  patients  from  oncology studies and patients from non-oncology studies.

The  safety  was  significantly  improved  with  masitinib  compared  to  sunitinib-treated  patients, which is a major benefit to the patients. Quality of life was also better with masitinib than with sunitinib.

Clinical Ground  No. 6 (CHMP has not taken into consideration the risk calculation comparing accelerated approval versus failure to accelerate approval): the applicant considered that the risk calculations  comparing  masitinib's  accelerated  approval  and  failure  to  accelerate  masitinib's

<div style=\"page-break-after: always\"></div>

approval should be taken into consideration to aid the EMA's decision. According to the applicant, the risk of masitinib being inferior in efficacy to sunitinib was &lt;.0001 and that there is a 90% risk that about 1000 patients/year will be harmed by withholding masitinib treatment.

Clinical Ground No. 7 (timely completion of further studies required for the confirmation of a positive benefit-risk balance cannot be expected in light of the observed recruitment so far in the ongoing confirmatory study): the applicant considered they would be able to provide comprehensive clinical data in a timely fashion upon completion of the ongoing phase III study by end of 2016.

Quality Ground  No. 1 (The starting material proposed by the applicant is considered a complex molecule  and  should  instead  be  considered  as  intermediate  of  the  synthesis):  The  applicant proposed  not  to  handle  the  material  as  an  intermediate  of  the  manufacturing  process  of  the active substance, i.e. redefining the starting material to an earlier stage of manufacture of the active substance, but to perform at a future date additional analytical development in order to demonstrate that the relevant impurities are well controlled and present at acceptable levels in the final product. The analytical development would focus on the control of these impurities.

Quality Ground  No. 2 (Unsatisfactory data was submitted to support the individual limit of not more  than  0.10  %  for  impurities  of  concern.  Similarly  the  limit  proposed  for  unspecified impurities  of  0.1  %  cannot  be  accepted  as  it  is  not  in  accordance  to  the  applicable  guidance considering the maximum daily dose of 1200 mg of masitinib): The applicant agreed to set the specification limits for the concerned impurities. In addition, the applicant proposed to lower the limit of total impurities to be closer to the current level, mainly observed in pilot batches.

Quality  Ground    No.  3 (Adequacy  of  the  proposed  particle  size  distribution  specification): Dissolution studies are ongoing to confirm the discriminatory nature of the present dissolution test  method,  and  if  necessary  a  new  dissolution  test  will  be  developed.  In  the  meantime,  the applicant proposed to revise specification for particle size distribution . When final dissolution test conditions are defined, the applicant proposes to revise, if necessary, the particle size limits on the  basis  of  the  particle  size  distribution  of  the  batches  of  active  substance  used  for  tablet batches of GIST clinical trials and demonstrated to have sufficient bioavailability (at least 85 % dissolved after 15 min).

Quality Ground  No. 4 (The compatibility studies of the active substance were not sufficient to support the compatibility of this new active substance with the excipients in the formulation): The applicant agreed that the compatibility investigation that was performed during formulation development is partial. Nevertheless, according to development methodology, such compatibility studies  are  made  during the  early  stage  of  development  to  prevent  risk  of  formulation  failure related to degradation phenomena over time during stability studies. The applicant referred to the long term stability data submitted to support the compatibility of the active substance with the excipients.

Quality Ground  No. 5 (The particle size of the active substance and core tablet hardness of the batches used in the clinical trials and batches of both strengths manufactured as proposed for the market vary significantly): With regard to particle size see quality ground No. 3. Concerning tablet  hardness:  Tthe  applicant  proposed  to  tighten  the  hardness  specifications  of  the  core tablets..

<div style=\"page-break-after: always\"></div>

Quality Ground  No. 6 (The data provided comparing the dissolution profiles between batches was  not  able  to  bridge  data  between  the  different  versions  of  the  product,  nor  support  the specification proposed for these parameters. This is of serious concern as the bioavailability of the active substance was not proven to be consistent between batches and no extrapolation to the intended critical quality attributes for commercial manufacture was possible): The applicant stated  that  additional  dissolution  studies  are  ongoing  for  demonstration  of  the  discriminatory nature of dissolution test, confirming that the 5 minutes test point will be investigated.

Quality Ground  No. 7 (The  applicant  failed  to  submit  data  in  support  of  the  discriminatory nature of the dissolution method. This is of major concern as the comparability exercise between biobatches  and  batches  manufactured  according  to  the  details  included  in  Module  3  are  not validated, moreover commercial batch release testing would not be able to detect batches with a potential  jeopardized  product  performance):  The  applicant  stated  that  additional  dissolution studies are ongoing for demonstration of the discriminatory nature of dissolution test.

Quality Ground  No. 8 (The validation data provided for analytical method was not sufficient with regards the methods for related substances determination and dissolution): The applicant stated that development of the improved impurity assay method is ongoing.

Quality  Ground  No.  9 (The  limit  still  to  be  defined  for  impurity  A,  found  to  be  thresholddependent genotoxic): The applicant proposes to tighten the limit of impurity A.

Following a request from the applicant at the time of the re-examination, the CHMP convened a Scientific Advisory Group (SAG) inviting the experts to provide their views on the CHMP grounds for refusal, taking into account the applicant's response.

## Report from the SAG

The questions addressed to the SAG by the CHMP were as follows:

1.  Does the SAG consider the difference observed between masitinib and sunitinib in the pivotal trial as a convincing and robust evidence for a clinical benefit? Please consider inclusion criteria (dose of imatinib at progression), trial conduct in respect of statistical methodology, primary and secondary hypotheses and hierarchy/contribution of all clinical efficacy endpoints.

The SAG considers that there is no convincing and robust evidence in terms of clinical benefit.

The pivotal study was a small exploratory randomized phase II trial. The efficacy is claimed on the basis of an observed difference in the secondary endpoint overall survival. The statistical significance of this observation is difficult to determine since the trial protocol did not aim to formally compare treatment groups and did not pre-specify adjustment for multiple efficacy analyses.

In order to rule out a chance finding, it is important to find supportive evidence to corroborate the claimed effect on overall survival. Supporting evidence from other efficacy endpoints or other clinical trials is lacking. No difference was observed in terms of progression-free survival or response rate or any other clinically relevant endpoint.

The discordance between overall survival and progression-free survival also raises the question about possible bias in the overall survival comparison due to possible imbalance in post-progression treatments. In theory the discordance may be explained by an

<div style=\"page-break-after: always\"></div>

immunological mechanism of action. However, this claim is based on in vitro data that are considered hypothesis generating and there is no clinical evidence to support this theory.

In conclusion, due to the statistical design and the lack of supportive evidence, the clinical benefit cannot be considered established. The claimed effect on overall survival can only be considered hypothesis generating (provided that important biases in terms of postprogression treatments can be ruled out).

This effect should be verified in a well-conducted confirmatory trial before any conclusions can be drawn. Validation of the immunological theory as part of translational research is recommended. Investigation of patient selection based on validated biomarkers using rigorous statistical methodology, is also recommended.

Based on the data presented, there are concerns about the feasibility of the ongoing phase III trial due to reported low recruitment (5 patients/month).

2.  Does the SAG consider the safety profile of masitinib as sufficiently characterized in the claimed indication at the proposed dosage?

Due to the limited number of patients with imatinib-resistant GIST in the safety database treated at the proposed dosage, the power to detect potentially rare and serious toxicity is low. Therefore, the toxicity profile cannot be considered as sufficiently characterised.

Notwithstanding this uncertainty, the toxicity observed in the pivotal study did not raise major concerns and compared favourably to sunitinib (e.g., lack of hand-foot syndrome). Arguably though, sunitinib dose is modulated in current clinical practice to manage toxicity compared to the fixed-dose approach previously used in the registration trials and clinical practice shortly after registration.

However, in the absence of established efficacy, the observed toxicity and uncertainty cannot be considered acceptable.

3.  The SAG should comment on the CHMP grounds for negative opinion (below) in view of the Applicant's grounds for re-examination submitted.

The efficacy of masitinib in GIST has not been sufficiently demonstrated;

The safety database is considered insufficient to allow an adequate assessment of the risks associated with masitinib in the proposed indication and posology;

The SAG broadly agreed with the CHMP grounds for negative opinion. The applicant's grounds for re-examination did not resolve the issues mentioned in the grounds for negative opinion (see answers to questions No. 1 and 2).

In view of the unmet need, if efficacy had been established, the uncertainty in the toxicity profile could probably be managed through adequate risk-management measures. However, in the absence of established efficacy, the toxicity cannot be considered acceptable.

<div style=\"page-break-after: always\"></div>

## Overall conclusion on grounds for re-examination

The CHMP assessed the detailed grounds for re-examination and argumentation presented by the applicant in writing and in the oral explanation and considered the views of the re-examination Scientific Advisory Group.

Concerning Clinical Ground No. 1, the CHMP maintained the view that from a statistical point of view any comparison between groups in the pivotal trial was exploratory, as stated in the study protocol; that pre-specification of secondary analyses or post-hoc handling of multiplicity using the  Bonferroni  method  for  selected  tests,  without  careful  pre-specification  of  handling  of multiplicity,  cannot  be  considered  adequate  to  control  the  Type  I  error,  based  on  general statistical  principles.  Furthermore,  OS  results  of  a  phase  I  trial  or  historical  comparisons  are difficult  to  interpret  and  cannot be considered as confirmatory due to possible bias, including selection  bias.  Thus,  based  on  exploratory  findings  of  a  difference  in  OS  without  supportive data, it is not possible to conclude that masitinib is associated with a benefit in terms of efficacy in the proposed indication and therefore a positive benefit-risk balance of the medicinal product as defined in Article 1(28a) of Directive 2001/83/EC has not been established.

Concerning Clinical Ground No. 2, if the main evidence of efficacy is from exploratory studies, it is  important  to  consider  the  degree  of  statistical  significance  and  internal  consistency  to corroborate  the  findings.  In  view  of  the  lack  of  an  effect  on  PFS  and  the  lack  of  other corroborating  evidence,  it  is  not  possible  to  conclude  with  confidence  that  masitinib  is associated with improvement in OS. The fact that PFS and other clinical endpoints are not valid surrogates  for  OS  for  a  number  of  treatments  and  indication  does  not  provide  useful corroborating evidence to address the existing uncertainty about the benefits associated with masitinib in the proposed indication.

Concerning Clinical Ground No. 3, the hypothesised immunological rationale for the mechanism of  action  lacks  verification  with  clinical  evidence.  Thus,  the  hypothesised  immunological rationale  does  not  provide  robust  corroborating  evidence  to  address  the  existing  uncertainty about the benefits associated with masitinib in the proposed indication.

Concerning Clinical  Ground No. 4, the CHMP agreed that submission of results from a single pivotal  trial  was  not  in  itself  blocking  approval  or  even  unusual  in  similar  oncology  settings. However,  due  to  the  methodological  deficiencies  and  lack  of  supportive  evidence  (see assessment of Clinical Grounds No. 1 and 2), there was insufficient evidence to conclude that masitinib is associated with a clinical benefit in the proposed indication and therefore a positive benefit-risk balance  of  the medicinal  product  as  defined  in  Article  1(28a) of Directive 2001/83/EC has not been established.

Concerning  Clinical  Ground  No.  5,  the  CHMP  concluded  that  the  toxicity  profile  cannot  be considered  as  sufficiently  characterised.  However,  the  CHMP  acknowledged  that  the  toxicity observed in the pivotal study did not establish grounds of a major concern. This is in line with the  advice  provided  by  the  Scientific  Advisory  Group.  The  uncertainty  in  the  toxicity  profile could  be  managed  through  adequate  risk-management  measures  however  efficacy  of  the medicinal product has not been established.

Concerning Clinical Ground No. 6, the CHMP considered that resampling methods are not useful to address the methodological deficiencies and lack of supportive evidence (see assessment of

<div style=\"page-break-after: always\"></div>

Clinical Grounds No. 1 and 2) and that therefore it is not possible to conclude that masitinib is associated with a benefit in the proposed indication. Due to this uncertainty, it is not possible to conclude that immediate availability of the medicinal product concerned outweighs the risks of lower efficacy compared to available treatment options. Furthermore, the resampling methodology used does not allow to conclude that the probability of masitinib being inferior in efficacy to sunitinib being &lt;.0001 based on general statistical principles. Similarly, it cannot be concluded that there is a 90% probability that about 1000 patients/year will be harmed, since this assumes that a benefit has been established for masitinib, which is not the case due to the aforementioned methodological deficiencies and lack of supportive evidence (see assessment of Clinical Grounds No. 1 and 2).

Concerning Clinical Ground No. 7, the CHMP noted that the applicant considered they would be able to provide comprehensive clinical data in a timely fashion upon completion of the ongoing phase III study by end of 2016. However, this does not address the current uncertainty about the benefits associated with masitinib in the proposed indication and therefore at this stage a positive benefit-risk balance of the medicinal product as defined in Article 1(28a) of Directive 2001/83/EC has not been established.

Concerning Quality Ground No. 1, the CHMP considered that the proposed starting material is a complex molecule with several possible routes of synthesis ways and manufacturers, and it is used in the last real synthesis step of the active substance (synthesis of masitinib base crude). The absence of regulatory oversight to a change in the synthesis of masitinib could lead to an unsatisfactory  and  uncontrolled  quality  of  the  finished  product,  with  a  potential  detrimental effect to the benefit risk of Masican. In addition, the proposal from the applicant not to redefine the  starting  material  would  not  provide  the  necessary  assurance  of  GMP  compliance  of  all critical manufacturing steps of the active substance.

Concerning Quality Ground No. 2, the CHMP noted that the applicant addressed the issue by tightening the limits of specified, unspecified and total impurities. This could be acceptable in principle,  subject  to  the  update  of  the  relevant  sections  of  Module  3  of  the  marketing authorisation dossier.

Concerning Quality Ground No. 3, the CHMP agreed with the applicant that the influence of the active substance particle size is minimal or at least not of major importance within the particle size specified if tested with the proposed dissolution medium (0.01 N HCl), that has so far not shown  to  be  discriminative.  The  real  concern  lies  on  the  lack  of  understanding  of  which conditions  of  the  manufacturing  process  justify  the  different  dissolution  results  observed, leading to a need to tighten to the necessary extent the available controls on the manufacturing process.  Therefore,  the  active  substance  specification  relating  to  particle  size  distribution  as proposed  by  the  applicant  is  still  not  acceptable  due  to  the  uncertainties  on  the  deficient understanding  of  the  manufacturing  process  -  the  particle  size  distribution  should  include D(0.1),  D(0.5)  and  D(0.9)  values  and  be  tightened  according  to  the  range  of  particle  size observed for the biobatches, where similar bioavailability has been demonstrated.

Concerning Quality Ground No. 4, the CHMP agreed with the rational provided by the applicant and the issue can be considered as resolved. To note that this was not a major objection.

Concerning Quality Ground No. 5, with regard to particle size, see quality ground No. 3 above. The tightened in process specification for hardness could be acceptable in principle, subject to

<div style=\"page-break-after: always\"></div>

the update of the relevant sections of Module 3 of the marketing authorisation dossier.

Concerning  Quality  Ground  No.  6,  the  CHMP  noted  that  a  post-authorisation  commitment relating to this point cannot be accepted and it is not ensured that the proposed testing time points would be sufficient. Additionally, it has to be considered that the dissolution profiles were established only with 0.01 N HCl as solvent (dissolution results at higher pH values were not provided but the dissolution of the drug substance is lowered at higher pH values) and that the discriminatory nature of the dissolution method was not demonstrated (see ground No. 7). The concern  on  the  lack  of  control  and  reproducibility  of  the  manufacturing  process  was  not addressed (see ground No. 3).

Concerning  Quality  Ground  No.  7,  the  CHMP  considered  that  confirmation  of  biobatch  vs. commercial batch comparability,  and  assurance  of  an  adequate  control  of  the  manufacturing process and quality of commercial batches need to be assured before a positive recommendation can be made on quality grounds.

Concerning Quality Ground No. 8, the CHMP concluded that the development of an improved complex  analytical  method  relating  to  the  impurity  testing  (including  additional  validation studies,  batch  results  and  stability  results)  should  not  be  handled  as  a  post  authorisation measure; see quality ground No. 1. Regarding the dissolution method, see quality ground No. 7.

Concerning Quality Ground No. 9, see quality grounds No. 2 and No. 5.

Overall, based on the assessment of the detailed grounds for re-examination submitted by the applicant, the CHMP concluded that the benefit-risk balance of Masican cannot be considered positive.

## Recommendations following re-examination

Based on the arguments of the applicant and all the supporting data on quality, safety and efficacy, the CHMP re-examined its initial opinion and in its final opinion concluded by consensus that the quality and efficacy of the above mentioned medicinal product are not sufficiently demonstrated, and, therefore recommends the refusal of the granting of the conditional Marketing Authorisation for the above mentioned medicinal product. The CHMP considers that:

- The efficacy of masitinib in GIST has not been sufficiently demonstrated;
- In the absence of established efficacy, a positive benefit-risk balance has not been established;
- The quality of the product is insufficiently controlled with regards patient exposure to impurities and the reproducibility between biobatches and commercial batches cannot be guaranteed.

Concerning clinical safety, aside from the existing uncertainties about the impact of patient exposure  to  potential  impurities  resulting  from  unregulated  changes  to  the  quality  of  the active  substance,  the  CHMP  concluded  that  although  toxicity  profile  cannot  be  considered sufficiently characterised, the toxicity observed in the pivotal study was not of major concern.

<div style=\"page-break-after: always\"></div>

The uncertainty in the toxicity profile could be managed through adequate risk-management measures, however efficacy of the medicinal product has not been established.

The CHMP considered that the requirements for a conditional approval laid down in Article 4 of  Commission  Regulation  (EC)  No  507/2006,  namely  the  benefit  risk  balance  of  the medicinal product, as defined in Article 1(28a) of Directive 2001/83/EC, is positive, has not been fulfilled.

Furthermore, the CHMP, in light of the negative recommendation, is of the opinion that it is not appropriate to conclude on the new active substance status at this time.